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Preamble
Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of assist-
ing health professionals in selecting the best management strategies
for an individual patient with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particu-
lar diagnostic or therapeutic means. Guidelines and recommenda-
tions should help health professionals to make decisions in their
daily practice. However, the final decisions concerning an individual
patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) as well as by other soci-
eties and organisations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The re-
commendations for formulating and issuing ESC Guidelines can be
found on the ESC Web Site (http://www.escardio.org/Guidelines-
&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official pos-
ition of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to
represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a
comprehensive review of the published evidence for management
(including diagnosis, treatment, prevention and rehabilitation) of
a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and
therapeutic procedures was performed, including assessment of
the risk–benefit ratio. Estimates of expected health outcomes for
larger populations were included, where data exist. The level of
evidence and the strength of the recommendation of particular
management options were weighed and graded according to prede-
fined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tions of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of inter-
est that arise during the writing period must be notified to the ESC
and updated. The Task Force received its entire financial support
from the ESC without any involvement from the healthcare
industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines produced by task forces, expert groups or consensus pa-
nels. The Committee is also responsible for the endorsement pro-
cess of these Guidelines. The ESC Guidelines undergo extensive
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review by the CPG and external experts. After appropriate revi-
sions the Guidelines are approved by all the experts involved
in the Task Force. The finalized document is approved by
the CPG for publication in the European Heart Journal. The Guide-
lines were developed after careful consideration of the scientific
and medical knowledge and the evidence available at the time of
their dating.
The task of developing ESC Guidelines covers not only the
integration of the most recent research, but also the creation of
educational tools and implementation programmes for the recom-
mendations. To implement all guidelines, condensed pocket guide-
lines versions, summary slides, booklets with essential messages,
summary cards for non-specialists, and an electronic version for
digital applications (smartphones, etc.) are produced. These ver-
sions are abridged and thus, if needed, one should always refer to
the full text version, which is freely available on the ESC website.
The National Societies of the ESC are encouraged to endorse,
translate and implement the ESC Guidelines. Implementation
programmes are needed because it has been shown that the out-
come of disease may be favourably influenced by the thorough ap-
plication of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as
in the determination and the implementation of preventive, diagnos-
tic or therapeutic medical strategies. However, the ESC Guidelines
do not override in any way whatsoever the individual responsibility
of health professionals to make appropriate and accurate decisions
in consideration of each patient’s health condition and in consult-
ation with that patient and the patient’s caregiver where appropriate
and/or necessary. It is also the health professional’s responsibility to
verify the rules and regulations applicable to drugs and devices at the
time of prescription.
1. Introduction
The pericardium (from the Greek p1ri´, ‘around’ and ka´rdion,
‘heart’) is a double-walled sac containing the heart and the roots
of the great vessels. The pericardial sac has two layers, a serous vis-
ceral layer (also known as epicardium when it comes into contact
with the myocardium) and a fibrous parietal layer. It encloses the
pericardial cavity, which contains pericardial fluid. The pericardium
fixes the heart to the mediastinum, gives protection against infection
and provides lubrication for the heart.
Pericardial diseases may be either isolated disease or part of a sys-
temic disease.1 –5 The main pericardial syndromes that are encoun-
tered in clinical practice include pericarditis (acute, subacute,
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 
clinical trial or large non-randomized 
studies. 
Level of 
evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to use
Class I Evidence and/or general 
agreement that a given treatment 
or procedure is beneficial, useful,
effective.
Is recommended/is 
indicated
Class II 
divergence of opinion about the 
Conflicting evidence and/or a
usefulness/efficacy of the given
favour of usefulness/efficacy.
Usefulness/efficacy is less well
treatment or procedure. 
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement 
that the given treatment or 
procedure is not useful/effective,  
and in some cases may be harmful. 
Is not recommended
ESC Guidelines2924
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chronic and recurrent), pericardial effusion, cardiac tamponade,
constrictive pericarditis and pericardial masses.1,4,5 All medical ther-
apies for pericardial diseases are off-label, since no drug has been re-
gistered until now for a specific pericardial indication.
1.1 What is new in pericardial diseases?
Pericardial diseases are relatively common in clinical practice and
new data have been published since the publication of the 2004
ESC Guidelines on pericardial diseases.1
New diagnostic strategies have been proposed for the triage of
patients with pericarditis and pericardial effusion and allow the se-
lection of high-risk patients to be admitted as well as when and how
additional diagnostic investigations are to be performed.4– 9 More-
over, specific diagnostic criteria have been proposed for acute and
recurrent pericarditis in clinical practice.2,4– 15
Multimodality imaging for pericardial diseases has become an es-
sential approach for a modern and comprehensive diagnostic evalu-
ation. Both the American Society of Echocardiography and the
European Association of Cardiovascular Imaging have provided rec-
ommendation documents in recent years.2,3
The aetiology and pathophysiology of pericardial diseases remain
to be better characterized, but new data supporting the immune-
mediated pathogenesis of recurrences and new forms related to
autoinflammatory diseases have been documented, especially in
paediatric patients.4,6 The first epidemiological data have become
available.7,16
Age and gender issues are now more evident and clear, including
specific recommendations for patients during pregnancy.17– 27
Major advances have occurred in therapy with the first multi-
centre randomized clinical trials.10,11,13 – 15 Colchicine has been
demonstrated as a first-line drug to be added to conventional anti-
inflammatory therapies in patients with a first episode of pericarditis
or recurrences in order to improve the response to therapy, in-
crease remission rates and reduce recurrences.10,11,13 – 15 Specific
therapeutic dosing without a loading dose and weight-adjusted
doses have been proposed to improve patient compliance.11,15
New therapeutic choices have become available for refractory
recurrent pericarditis, including alternative immunosuppressive
therapies (e.g. azathioprine), intravenous immunoglobulins (IVIGs)
and interleukin-1 (IL-1) antagonists (e.g. anakinra).20 – 23,28 – 32
Pericardiectomy has been demonstrated as a possible valuable
alternative to additional medical therapies in patients with re-
fractory recurrent pericarditis.33 The first large prospective and
retrospective studies (.100 patients) have investigated the prog-
nosis and complication risk in patients with acute and recurrent
pericarditis.7,9,34 – 38
Imaging techniques for the detection of pericardial inflammation
[e.g. cardiac magnetic resonance (CMR)] may identify forms of initial
reversible constrictive pericarditis, allowing a trial of medical anti-
inflammatory therapy that may reduce the need for surgery.2,39– 41
In conclusion, significant new data have become available since
2004, and a new version of guidelines has become mandatory for
clinical practice. Nevertheless, in the field of pericardial diseases
there are a limited number of randomized controlled trials
(RCTs). Therefore the number of class I level A indications are
limited.
2. Epidemiology, aetiology and
classification of pericardial diseases
2.1 Epidemiology
Despite the relative high frequency of pericardial diseases, there are
few epidemiological data, especially from primary care. Pericarditis
is the most common disease of the pericardium encountered in clin-
ical practice. The incidence of acute pericarditis has been reported
as 27.7 cases per 100,000 population per year in an Italian urban
area.7 Pericarditis is responsible for 0.1% of all hospital admissions
and 5% of emergency room admissions for chest pain.4,5,42 Data col-
lected from a Finnish national registry (2000–9) showed a standar-
dized incidence rate of hospitalizations for acute pericarditis of 3.32
per 100,000 person-years.16 These data were limited to hospitalized
patients and therefore may account for only a minority of cases, as
many patients with pericarditis are commonly not admitted to hos-
pital.8,9,42,43 Men ages 16–65 years were at higher risk for pericar-
ditis (relative risk 2.02) than women in the general admitted
population, with the highest risk difference among young adults
compared with the overall population. Acute pericarditis caused
0.20% of all cardiovascular admissions. The proportion of caused ad-
missions declined by an estimated 51% per 10-year increase in age.
The in-hospital mortality rate for acute pericarditis was 1.1% and
was increased with age and severe co-infections (pneumonia or
septicaemia).16 However, this is a study based on hospital admis-
sions only. Recurrences affect about 30% of patients within
18 months after a first episode of acute pericarditis.10,11
2.2 Aetiology
A simple aetiological classification for pericardial diseases is to
consider infectious and non-infectious causes (Table 3).4,6,12,44 The
aetiology is varied and depends on the epidemiological background,
patient population and clinical setting. In developed countries,
viruses are usually the most common aetiological agents of pericar-
ditis,6 whereas tuberculosis (TB) is the most frequent cause of
pericardial diseases in the world and developing countries, where
TB is endemic. In this setting, TB is often associated with human
immunodeficiency virus (HIV) infection, especially in sub-Saharan
Africa.44
3. Pericardial syndromes
Pericardial syndromes include different clinical presentations of
pericardial diseases with distinctive signs and symptoms that can
be grouped in specific ‘syndromes’. The classical pericardial syn-
dromes include pericarditis, pericardial effusion, cardiac tamponade
and constrictive pericarditis. Pericardial effusion and cardiac tam-
ponade may occur without pericarditis and will be considered in
separate chapters. Specific considerations apply to cases with peri-
carditis and concomitant myocardial inflammatory involvement,
usually referred to in the literature as ‘myopericarditis’.
3.1 Acute pericarditis
Acute pericarditis is an inflammatory pericardial syndrome with or
without pericardial effusion.1 – 11,42 The clinical diagnosis can be
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made with two of the following criteria (Table 4):2,4 –15 (i) chest pain
(.85–90% of cases)—typically sharp and pleuritic, improved by sit-
ting up and leaning forward; (ii) pericardial friction rub (≤33% of
cases)—a superficial scratchy or squeaking sound best heard with
the diaphragm of the stethoscope over the left sternal border;
(iii) electrocardiogram (ECG) changes (up to 60% of cases)—with
new widespread ST elevation or PR depression in the acute phase
(Web Figure 1); and (iv) pericardial effusion (up to 60% of cases, gen-
erally mild) (Web Figure 2). Additional signs and symptoms may be
present according to the underlying aetiology or systemic disease
(i.e. signs and symptoms of systemic infection such as fever and
leucocytosis, or systemic inflammatory disease or cancer).45
Widespread ST-segment elevation has been reported as a
typical hallmark sign of acute pericarditis (Web Figure 1). However,
changes in the ECG imply inflammation of the epicardium,
since the parietal pericardium itself is electrically inert.5 – 7,34
Typical ECG changes have been reported in up to 60% of
cases.10,11 The temporal evolution of ECG changes with acute
pericarditis is highly variable from one patient to another and is
affected by therapy. Major differential diagnoses include acute
coronary syndromes with ST-segment elevation and early
repolarization.6,12,46
Elevation of markers of inflammation [i.e. C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR), as well as
elevation of the white blood cell count] is a common and support-
ive finding in patients with acute pericarditis and may be helpful
for monitoring the activity of the disease and efficacy of
therapy.2,47 Patients with concomitant myocarditis may present
with an elevation of markers of myocardial injury [i.e. creatine ki-
nase (CK), troponin].7,34
Table 3 Aetiology of pericardial diseases. The
pericardium may be affected by all categories of
diseases, including infectious, autoimmune, neoplastic,
iatrogenic, traumatic, and metabolic
A. Infectious causes: 
Viral (common): Enteroviruses (coxsackieviruses, echoviruses),
herpesviruses (EBV, CMV, HHV-6), adenoviruses, parvovirus B19 (possible 
overlap with aetiologic viral agents of myocarditis). 
Bacterial: Mycobacterium tuberculosis (common, other bacterial 
rare), Coxiella burnetii, Borrelia burgdorferi, rarely: Pneumococcus spp, 
Meningococcus spp, Gonococcus spp, Streptococcus spp, Staphylococcus 
spp, Haemophilus spp, Chlamydia spp, Mycoplasma spp, Legionella spp, 
Leptospira spp, Listeria spp, Providencia stuartii.
Fungal (very rare): Histoplasma spp (more likely in immunocompetent 
patients), Aspergillus spp, Blastomyces spp, Candida spp (more likely in 
immunocompromised host).
Parasitic (very rare): Echinococcus spp, Toxoplasma spp
B. Non-infectious causes:
Autoimmune (common):
erythematosus, Sjögren syndrome, rheumatoid arthritis, scleroderma), 
systemic vasculitides (i.e. eosinophilic granulomatosis with polyangiitis 
or allergic granulomatosis, previously named Churg-Strauss syndrome, 
Horton disease, Takayasu disease, Behçet syndrome), sarcoidosis, familial 
Neoplastic:
Primary tumours (rare, above all pericardial mesothelioma).
Secondary metastatic tumours (common, above all lung and breast cancer, 
lymphoma). 
Metabolic: Uraemia, myxoedema, anorexia nervosa, other rare.
Early onset (rare):
•  Direct injury (penetrating thoracic injury, aesophageal perforation).
•  Indirect injury (non-penetrating thoracic injury, radiation injury).
Delayed onset: Pericardial injury syndromes (common) such as
postmyocardial infarction syndrome, postpericardiotomy syndrome,
posttraumatic,  including forms  after iatrogenic trauma (e.g. coronary
percutaneous intervention, pacemaker lead insertion and radiofrequency
ablation). 
Drug-related (rare): Lupus-like syndrome (procainamide, hydralazine,
methyldopa, isoniazid, phenytoin); antineoplastic drugs (often associated with a 
cardiomyopathy, may cause a pericardiopathy): doxorubicin, daunorubicin, 
hypersensitivity pericarditis with eosinophilia; amiodarone,  methysergide, 
mesalazine, clozapine, minoxidil, dantrolene, practolol, phenylbutazone, 
thiazides, streptomycin, thiouracils, streptokinase, p-aminosalicylic acid, sulfa-
drugs, cyclosporine, bromocriptine, several vaccines, GM-CSF, anti-TNF 
agents.
Other (common): Amyloidosis, aortic dissection, pulmonary arterial 
hypertension and chronic heart failure.
Other (uncommon): congenital partial and complete absence of the 
pericardium.
Traumatic and Iatrogenic:
CMV ¼ cytomegalovirus; EBV ¼ Epstein-Barr virus; GM-CSF ¼
granulocyte-macrophage colonystimulating factor; HHV ¼ human herpesvirus;
spp ¼ species; TNF ¼ tumor necrosis factor.
Table 4 Definitions and diagnostic criteria for
pericarditis (see text for explanation)
Acute
with at least 2 of the 4 following criteria:
 (1) pericarditic chest pain
 (2) pericardial rubs
 (3) new widespread ST-elevation or PR depression 
Additional supporting findings:
  on ECG
 (4) pericardial effusion (new or worsening)
 - Ele
  C-reactive protein, erythrocyte sedimentation 
  rate, and white blood cell count);
 - Evidence of pericar
  imaging technique (CT, CMR).
Incessant Pericarditis lasting for >4–6 weeks but <3 months  
without remission.
Recurrent
episode of acute pericarditis and a symptom-free 
interval of 4–6 weeks or longera.
Chronic Pericarditis lasting for >3 months.
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography;
ECG ¼ electrocardiogram.
aUsually within 18–24 months but a precise upper limit of time has not been
established.
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A chest X-ray is generally normal in patients with acute
pericarditis since an increased cardiothoracic ratio only occurs
with pericardial effusions exceeding 300 ml.48 In the case of pleur-
opulmonary diseases, signs of pleuropericardial involvement may be
found in patients with pericarditis.2,3
Recommendations for diagnosis of acute pericarditis
Recommendations Classa Levelb Ref.c
ECG is recommended in all patients with
suspected acute pericarditis
I C
Transthoracic echocardiography is
recommended in all patients with
suspected acute pericarditis
I C
Chest X-ray is recommended in all
patients with suspected acute
pericarditis
I C
Assessment of markers of
inflammation (i.e. CRP) and myocardial
injury (i.e. CK, troponin) is
recommended in patients with
suspected acute pericarditis
I C
CK ¼ creatine kinase; CRP ¼ C-reactive protein; ECG ¼ electrocardiogram.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.1.1 Clinical management and therapy
It is not mandatory to search for the aetiology in all patients, espe-
cially in countries with a low prevalence of TB, because of the rela-
tively benign course associated with the common causes of
pericarditis and the relatively low yield of diagnostic inves-
tigations.6,8,12,49 Specific final identifiable causes (non-viral –
non-idiopathic) as well as high-risk features in the context of acute
pericarditis have been identified as being associated with an in-
creased risk of complications during follow-up (tamponade, recur-
rences and constriction).9,12,43,50 The major risk factors associated
with poor prognosis after multivariate analysis include high fever
[.388C (.100.48F)], subacute course (symptoms over several
days without a clear-cut acute onset), evidence of large pericardial
effusion (i.e. diastolic echo-free space .20 mm), cardiac tampon-
ade and failure to respond within 7 days to non-steroidal anti-
inflammatory drugs (NSAIDs).9,43,50 Other risk factors should also
be considered (i.e. ‘minor risk factors’); these are based on expert
opinion and literature review, including pericarditis associated
with myocarditis (myopericarditis), immunodepression, trauma
and oral anticoagulant therapy.
On this basis a triage for acute pericarditis is proposed (Figure 1,
Web Table 6).5,6,43 Any clinical presentation that may suggest an
underlying aetiology (e.g. a systemic inflammatory disease) or
with at least one predictor of poor prognosis (major or minor
risk factors) warrants hospital admission and an aetiology
search.9,43,49 – 51 On the other hand, patients without these
features can be managed as outpatients with empiric anti-
inflammatories and short-term follow-up after 1 week to assess
the response to treatment.9
Recommendations for the management of acute
pericarditis
Recommendations Classa Levelb Ref.c
Hospital admission is recommended for
high-risk patients with acute pericarditis
(at least one risk factord)
I B 8,9
Outpatient management is
recommended for low-risk patients with
acute pericarditis
I B 8,9
Evaluation of response to
anti-inflammatory therapy is
recommended after 1 week
I B 8,9
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dSee Figure 1 (both major and minor predictors of poor prognosis).
In patients identified with a cause other than viral infection, spe-
cific therapy appropriate to the underlying disorder is indi-
cated49,51 and the epidemiological background (high vs. low
prevalence of TB) should be considered.8,12,52 The first non-
pharmacological recommendation is to restrict physical activity
beyond ordinary sedentary life until resolution of symptoms and
normalization of CRP for patients not involved in competitive
sports.53 Athletes are recommended to return to competitive
sports only after symptoms have resolved and diagnostic tests
(i.e. CRP, ECG and echocardiogram) have been normalized.53,54
A minimal restriction of 3 months (after the initial onset of the at-
tack) has been arbitrarily defined according to expert consensus.54
We suggest applying this restriction only to athletes, while a
shorter period (until remission) may be suitable for non-athletes.
Aspirin or NSAIDs are mainstays of therapy for acute peri-
carditis.5,6,55,56 Different anti-inflammatory drugs have been pro-
posed (Table 5).
The choice of drug should be based on the history of the patient
(contraindications, previous efficacy or side effects), the presence of
concomitant diseases (favouring aspirin over other NSAIDs when
aspirin is already needed as antiplatelet treatment) and physician
expertise.56
Colchicine is recommended at low, weight-adjusted doses to
improve the response to medical therapy and prevent recur-
rences.10,11,57 – 59 Tapering of colchicine is not mandatory but
may be considered to prevent persistence of symptoms and re-
currence.5,6,56 Corticosteroids should be considered as a second
option in patients with contraindications and failure of aspirin or
NSAIDs because of the risk of favouring the chronic evolution of
the disease and promoting drug dependence; in this case
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they are used with colchicine. If used, low to moderate doses (i.e.
prednisone 0.2–0.5 mg/kg/day or equivalent) should be recom-
mended instead of high doses (i.e. prednisone 1.0 mg/kg/day or
equivalent).35 The initial dose should be maintained until reso-
lution of symptoms and normalization of CRP, then tapering
should be considered.5,6,35,47,56
Pericarditis?
(physical examination, ECG, chest x-ray,
echacardiogram, CRP, troponin)
NO
Diagnostic criteria not satisfied.
Search for alternative diagnoses
YES
Specific aetiology highly suspected or
any predictor of poor prognosis
YES NO
Empiric trial with NSAID
NO YES
MODERATE RISK CASES
Admission and aetiology search
LOW RISK CASES
Outpatient follow-up
HIGH RISK CASES
Admission and aetiology search
(major or minor prognostic predictor)
NON-HIGH RISK CASES
No admission and etiology search.
Response to NSAID?
Predictors of poor prognosis:
Major
• Fever >38°C
• Subacute onset
• Large pericardial effusion
• Cardiac tamponade
• Lack of response to aspirin or NSAIDs 
  after at least 1 week of therapy
Minor
• Myopericarditis
• Immunosuppression
• Trauma
• Oral anticoagulant therapy
CRP = C-reactive protein; ECG = electrocardiogram. 
Figure 1 Proposed triage of pericarditis.
Table 5 Commonly prescribed anti-inflammatory therapy for acute pericarditis
Drug Usual dosinga Tx durationb Taperinga
Aspirin 750–1000 mg every 8h 1–2 weeks Decrease doses by 250–500 mg every 1–2 weeks
Ibuprofen 600 mg every 8h 1–2 weeks Decrease doses by 200–400 mg every 1–2 weeks
Colchicine 0.5 mg once (<70 kg) or 0.5 mg b.i.d. 
(≥70 kg)
3 months Not mandatory, alternatively 0.5 mg every other day 
(< 70 kg) or 0.5 mg once (≥70 kg) in the last weeks
b.i.d. ¼ twice daily; CRP ¼ C-reactive protein; NSAIDs ¼ non-steroidal anti-inflammatory drugs; Tx ¼ treatment.
aTapering should be considered for aspirin and NSAIDs.
bTx duration is symptoms and CRP guided but generally 1–2 weeks for uncomplicated cases. Gastroprotection should be provided. Colchicine is added on top of aspirin or
ibuprofen.
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Recommendations for the treatment of acute
pericarditis
Recommendations Classa Levelb Ref.c
Aspirin or NSAIDs are recommended as
first-line therapy for acute pericarditis
with gastroprotection
I A 55
Colchicine is recommended as first-line
therapy for acute pericarditis as an
adjunct to aspirin/NSAID therapy
I A
10,11,
58,59
Serum CRP should be considered to
guide the treatment length and assess
the response to therapy
IIa C
Low-dose corticosteroidsd should be
considered for acute pericarditis in cases
of contraindication/failure of aspirin/
NSAIDs and colchicine, and when an
infectious cause has been excluded, or
when there is a specific indication such
as autoimmune disease
IIa C
Exercise restriction should be
considered for non-athletes with acute
pericarditis until resolution of symptoms
and normalization of CRP, ECG and
echocardiogram
IIa C
For athletes, the duration of exercise
restriction should be considered until
resolution of symptoms and
normalization of CRP, ECG and
echocardiogram—at least 3 months is
recommended
IIa C
Corticosteroids are not recommended
as first-line therapy for acute pericarditis
III C
CRP ¼ C-reactive protein; ECG ¼ electrocardiogram; NSAIDs ¼ non-steroidal
anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dAdded to colchicine.
3.1.2 Prognosis
Most patients with acute pericarditis (generally those with pre-
sumed viral or idiopathic pericarditis) have a good long-term prog-
nosis.36 Cardiac tamponade rarely occurs in patients with acute
idiopathic pericarditis, and is more common in patients with a spe-
cific underlying aetiology such as malignancy, TB or purulent peri-
carditis. Constrictive pericarditis may occur in ,1% of patients
with acute idiopathic pericarditis, and is also more common in pa-
tients with a specific aetiology. The risk of developing constriction
can be classified as low (,1%) for idiopathic and presumed viral
pericarditis; intermediate (2–5%) for autoimmune, immune-
mediated and neoplastic aetiologies; and high (20–30%) for bacter-
ial aetiologies, especially with TB and purulent pericarditis.36
Approximately 15–30% of patients with idiopathic acute pericardi-
tis who are not treated with colchicine will develop either recurrent
or incessant disease, while colchicine may halve the recurrence
rate.10,11,13– 15
3.2 Incessant and chronic pericarditis
The term ‘incessant’ has been adopted for cases with persistent
symptoms without a clear-cut remission after the acute episode.
The term ‘chronic’ generally refers—especially for pericardial effu-
sions—to disease processes lasting .3 months.48 The Task Force
suggests that the term ‘acute’ should be adopted for new-onset
pericarditis, ‘incessant’ for pericarditis with symptoms persisting
for .4–6 weeks (that is generally the approximate length of con-
ventional anti-inflammatory therapy and its tapering),11,60 and
‘chronic’ for pericarditis lasting .3 months.
3.3 Recurrent pericarditis
Recurrent pericarditis is diagnosed with a documented first episode
of acute pericarditis, a symptom-free interval of 4–6 weeks or
longer and evidence of subsequent recurrence of pericarditis
(Table 4).11,13 – 15 Diagnosis of recurrence is established according
to the same criteria as those used for acute pericarditis. CRP,2,47
computed tomography (CT) and/or CMR may provide confirma-
tory findings to support the diagnosis in atypical or doubtful cases
showing pericardial inflammation through evidence of oedema
and contrast enhancement of the pericardium.2,39
The recurrence rate after an initial episode of pericarditis ranges
from 15 to 30%,10,11 and may increase to 50% after a first recurrence
in patients not treated with colchicine,13 – 15 particularly if treated
with corticosteroids.
In developed countries, the aetiology is often not identified in
most immunocompetent patients, and it is generally presumed to
be immune-mediated.60– 62 A common cause of recurrence is inad-
equate treatment of the first episode of pericarditis. In up to 20% of
cases, when additional virological studies have been conducted on
pericardial fluid and tissue, a viral aetiology is detected.63
3.3.1 Therapy
Recurrent pericarditis therapy should be targeted at the underlying
aetiology in patients with an identified cause. Aspirin or NSAIDs re-
main the mainstay of therapy (Table 6, Web Box, Web Table 1A). Col-
chicine is recommended on top of standard anti-inflammatory
therapy, without a loading dose and using weight-adjusted doses
(i.e. 0.5 mg once daily if body weight is ,70 kg or 0.5 mg twice daily
if it is ≥70 kg, for ≥6 months) (Table 6, Web Table 1B) in order to
improve the response to medical therapy, improve remission rates
and prevent recurrences.13–15,58,59
In cases of incomplete response to aspirin/NSAIDs and colchi-
cine, corticosteroids may be used, but they should be added at
low to moderate doses to aspirin/NSAIDs and colchicine as triple
therapy, not replace these drugs, in order to achieve better control
of symptoms. Corticosteroids at low to moderate doses (i.e. pred-
nisone 0.2–0.5 mg/kg/day) should be avoided if infections, particu-
larly bacterial and TB, cannot be excluded and should be
restricted to patients with specific indications (i.e. systemic inflam-
matory diseases, post-pericardiotomy syndromes, pregnancy) or
NSAID contraindications (true allergy, recent peptic ulcer or
gastrointestinal bleeding, oral anticoagulant therapy when the
bleeding risk is considered high or unacceptable) or intolerance
or persistent disease despite appropriate doses.58 Although corti-
costeroids provide rapid control of symptoms, they favour
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chronicity, more recurrences and side effects.35,55,61 If corticoster-
oids are used, their tapering should be particularly slow. A critical
threshold for recurrences is a 10–15 mg/day dose of prednisone
or equivalent. At this threshold, very slow decrements as small as
1.0–2.5 mg at intervals of 2–6 weeks are useful. In cases of recur-
rence, every effort should be made not to increase the dose or to
reinstate corticosteroids (Tables 6 and 7).5,6,35,61
After obtaining a complete response, tapering should be done
with a single class of drug at a time before colchicine is gradually dis-
continued (over several months in the most difficult cases). Recur-
rences are possible after discontinuation of each drug. Each tapering
should be attempted only if symptoms are absent and CRP is
normal.5,6,47,56 The Task Force does not recommend influenza vac-
cine as a preventive measure for pericarditis in patients with recur-
rent pericarditis, since the influenza virus is not a usual cause of
pericarditis. The influenza vaccine should be administered according
to specific indications beyond pericarditis; moreover, recurrences
are generally immune mediated, and inappropriate or unwanted
stimulation of the immune system may trigger or worsen an episode
of pericarditis.
An alternative effective approach to minimize systemic side ef-
fects related to corticosteroids may be intrapericardial administra-
tion of non-absorbable corticosteroids,64,65 but this technique
requires further investigation. For those patients who require un-
acceptably high long-term doses of corticosteroids (e.g. prednisone
15–25 mg/day) or who do not respond to anti-inflammatory ther-
apies, several drugs have been used, including azathioprine,28 IVIG
(immunomodulatory but also anti-viral)29,30 and anakinra, a recom-
binant IL-1b receptor antagonist,31,32 but strong evidence-based
data are lacking (Web Table 2). Other immunosuppressive drugs
[i.e. cyclophosphamide, cyclosporine, methotrexate, hydroxychlor-
oquine, anti-tumour necrosis factor (TNF) agents] have been only
anecdotally reported. Less toxic agents might be preferred, and
eventually combined, with the therapy being tailored to the individ-
ual patient and physician experience (Figure 2). Azathioprine is main-
ly a slow-acting corticosteroid-sparing agent, useful to control the
disease for a long-term follow-up, while anakinra and IVIG are
effective during the acute phase, though recurrences may occur
after discontinuation.29 – 32 Drugs such as IVIG, anakinra and
azathioprine may be considered in cases of proven infection-
negative, corticosteroid-dependent, recurrent pericarditis not re-
sponsive to colchicine after careful assessment of the costs, risks
and eventually consultation by multidisciplinary experts, including
immunologists and/or rheumatologists, in the absence of a specific
expertise. It is also mandatory to educate the patient and his/her
caregivers about the clinical risks related to immunomodulatory/im-
munosuppressive drugs and the safety measures to adopt during the
treatment. As a last resort, pericardiectomy may be considered, but
only after a thorough trial of unsuccessful medical therapy, and with
referral of the patient to a centre with specific expertise in this sur-
gery.33 The physical activity restrictions in acute pericarditis apply
also to recurrences.53,54
Table 6 Commonly prescribed anti-inflammatory therapies for recurrent pericarditis (for further details see Web
Tables 1A and 1B)
Drug Usual initial dosea Tx durationb Taperinga
Aspirin 500–1000 mg every 6–8 hours (range 1,5–4 g/day) weeks-months Decrease doses by 250–500 mg every 1–2 weeksb
Ibuprofen 600 mg every 8 hours (range 1200–2400 mg) weeks-months Decrease doses by 200–400 mg every 1–2 weeksb
Indomethacin 25–50 mg every 8 hours: start at lower end of 
dosing range and titrate upward to avoid headache 
and dizziness.
weeks-months Decrease doses by 25 mg every 1–2 weeksb
Colchicine 0.5 mg twice or 0.5 mg daily for patients <70 kg or 
intolerant to higher doses.
At least 6 months Not necessary, alternatively 0.5 mg every other day 
(<70 kg) or 0.5 mg once (≥70 kg) in the last weeks
Tx ¼ treatment.
aTapering should be considered for aspirin and NSAIDs.
bLonger tapering times for more difficult, resistant cases may be considered.
Table 7 Tapering of corticosteroids35 (dosage
information is provided for prednisone)
Starting dose 0.25–0.50 mg/kg/daya Taperingb
>50 mg 10 mg/day every 1–2 weeks
50–25 mg 5–10 mg/day every 1–2 weeks
25–15 mg 2.5 mg/day every 2–4 weeks
<15 mg 1.25–2.5 mg/day every
2–6 weeks
aAvoid higher doses except for special cases, and only for a few days, with rapid
tapering to 25 mg/day. Prednisone 25 mg are equivalent to methylprednisolone 20
mg.
bEvery decrease in prednisone dose should be done only if the patient is
asymptomatic and C-reactive protein is normal, particularly for doses,25 mg/day.
Calcium intake (supplement plus oral intake) 1,200–1,500 mg/day and vitamin D
supplementation 800–1000 IU/day should be offered to all patients receiving
glucocorticoids. Moreover, bisphosphonates are recommended to prevent bone
loss in all men ≥50 years and postmenopausal women in whom long-term
treatment with glucocorticoids is initiated at a dose ≥5.0–7.5 mg/day of
prednisone or equivalent.
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Recommendations for the management of recurrent
pericarditis
Recommendations Classa Levelb Ref.c
Aspirin and NSAIDs are mainstays of
treatment and are recommended at full
doses, if tolerated, until complete
symptom resolution
I A 55,56
Colchicine (0.5 mg twice daily or 0.5 mg
daily for patients,70 kg or intolerant to
higher doses); use for 6 months is
recommended as an adjunct to aspirin/
NSAIDs
I A
13–15,
58,59
Colchicine therapy of longer duration
(.6 months) should be considered in
some cases, according to clinical
response
IIa C
CRP dosage should be considered to
guide the treatment duration and assess
the response to therapy
IIa C
After CRP normalization, a gradual
tapering of therapies should be
considered, tailored to symptoms and
CRP, stopping a single class of drugs at a
time
IIa C
Drugs such as IVIG, anakinra and
azathioprine may be considered in cases
of corticosteroid-dependent recurrent
pericarditis in patients not responsive to
colchicine
IIb C
Exercise restriction should be
considered for non-athletes with
recurrent pericarditis until symptom
resolution and CRP normalization,
taking into account the previous history
and clinical conditions
IIa C
Exercise restriction for a minimum of
3 months should be considered
for athletes with recurrent pericarditis
until symptom resolution and
normalization of CRP, ECG and
echocardiogram
IIa C
Diagnosis of acute pericarditis
(2 of 4 clinical criteria: pericardial chest pain, pericardial rubs, ECG changes; pericardial effusion)
Recurrent pericarditis
(after symptom-free interval 4–6 weeks)
Aspirin or NSAID + colchicine + exercise restriction
Low-dose corticosteroids
(in case of contraindications to aspirin/NSAID/colchicine and after exclusion of infectious cause)
Aspirin or NSAID + colchicine + exercise restriction
i.v. immunoglobulin or anakinra or azathioprinea
Pericardiectomy
Low-dose corticosteroids
(in case of contraindications to aspirin/NSAID/colchicine and after exclusion of infectious cause)
First line
Second line
First line
Second line
Third line
Fourth line
Low-dose corticosteroids are considered when there are contraindications to other drugs or when there is an incomplete response to aspirin/NSAIDs plus colchicine; in this case 
a
(e.g. azathioprine) and resorting to more expensive options (e.g. IVIG and anakinra) for refractory cases.
Figure 2 Therapeutic algorithm for acute and recurrent pericarditis (see text for explanation).
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If ischaemic heart disease is a concern or
antiplatelet therapy is required, aspirin
should be considered, at medium high
doses (1–2.4 g/day)* (Web box)
IIa C
If symptoms recur during therapy
tapering, the management should
consider not increasing the dose of
corticosteroids to control symptoms,
but increasing to the maximum dose of
aspirin or NSAIDs, well distributed,
generally every 8 hours, and
intravenously if necessary, adding
colchicine and adding analgesics for pain
control
IIa C
Corticosteroid therapy is not
recommended as a first line-approach III B
13–15,
35,37,
55
CRP ¼ C-reactive protein; ECG ¼ electrocardiogram; IVIG ¼ intravenous
immunoglobulin; NSAIDs ¼ non-steroidal anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.3.2 Prognosis
Severe complications are uncommon in idiopathic recurrent peri-
carditis.37,60,61 Cardiac tamponade is rare and generally occurs at
the beginning of the disease. Constrictive pericarditis has never
been reported in these patients, despite numerous recurrences,
and the overall risk is lower than that recorded after a first episode
of acute pericarditis (,1%).36,37,61 Thus it is important to reassure
patients about their prognosis, explaining the nature of the disease
and its likely course. The complication rates are related to the aeti-
ology and not to the number of recurrences. Drug treatment should
take into account this favourable outcome to avoid more toxic
agents. However, quality of life can be severely affected in patients
with repeated recurrences, subacute or incessant pericarditis and
glucocorticoid dependence.
3.4 Pericarditis associated with
myocardial involvement
(myopericarditis)
Pericarditis and myocarditis share common aetiologies, and overlap-
ping forms may be encountered in clinical practice.34,66 Pericarditis
with known or clinically suspected concomitant myocardial involve-
ment should be referred to as ‘myopericarditis’, while predominant
myocarditis with pericardial involvement should be referred to as
‘perimyocarditis’, according to Task Force consensus. The classical
presentation is chest pain associated with other signs of pericarditis
(pericardial rubs, ST-segment elevation and pericardial effusion)
plus the elevation of markers of myocardial damage (i.e. troponins).
Limited clinical data on the causes of myopericarditis suggest that
viral infections are among the most common causes in developed
countries, while other infectious causes are more common in devel-
oping countries (especially TB). Cardiotropic viruses can cause peri-
cardial and myocardial inflammation via direct cytolytic or cytotoxic
effects and/or subsequent immune-mediated mechanisms. Such
mechanisms are especially involved in cases associated with con-
nective tissue diseases, inflammatory bowel diseases and
radiation-induced, drug-induced or vaccinia-associated myopericar-
dial involvement. Many cases of myopericarditis are subclinical. In
other patients, cardiac symptoms and signs are masked by pro-
nounced systemic manifestations of infection or inflammation.66 In
many cases, myopericarditis manifestations are preceded by or
are sometimes concomitant with an acute respiratory illness (espe-
cially acute tonsillitis, pneumonia) or gastroenteritis. The increased
sensitivity of troponin assays and contemporary widespread use
of troponins has greatly increased the reported number of
cases.7,34,66–68
3.4.1 Definition and diagnosis
The diagnosis of predominant pericarditis with myocardial involve-
ment, or ‘myopericarditis’, can be clinically established if patients
with definite criteria for acute pericarditis show elevated biomar-
kers of myocardial injury (troponin I or T, CK-MB fraction) without
newly developed focal or diffuse impairment of left ventricular func-
tion in echocardiography or CMR.34 The term myopericarditis indi-
cates a primarily pericarditic syndrome with minor myocardial
involvement, which describes the majority of combined pericarditis
and myocarditis cases encountered in clinical practice.7,9,34,68
On the other hand, evidence of new-onset focal or diffuse reduc-
tion of left ventricular function in patients with elevated myocardial
biomarkers and clinical criteria for acute pericarditis suggests pre-
dominant myocarditis with pericardial involvement (‘perimyocardi-
tis’).34,66 Definite confirmation of the presence of myocarditis will
require endomyocardial biopsy according to the Myocardial and
Pericardial Diseases Working Group position statement.69 How-
ever, the benign prognosis of patients with suspected concomitant
myocardial involvement in predominant pericarditis (myopericardi-
tis), with absent or mild left ventricular dysfunction, and no symp-
toms of heart failure does not clinically require endomyocardial
biopsy.6,34,66–68,70,71
In cases of pericarditis with suspected associated myocarditis,
coronary angiography (according to clinical presentation and risk
factor assessment) is recommended in order to rule out acute cor-
onary syndromes. CMR is recommended for the confirmation of
myocardial involvement and to rule out ischaemic myocardial ne-
crosis in the absence of significant coronary disease; this has clinical
and therapeutic implications.34,66
3.4.2 Management
Hospitalization is recommended for diagnosis and monitoring of
patients with myocardial involvement and differential diagnosis,
especially with acute coronary syndromes. In the setting of myoper-
icarditis, management is similar to that recommended for pericardi-
tis. Empirical anti-inflammatory therapies (i.e. aspirin 1500–3000
mg/day) or NSAIDs (ibuprofen 1200–2400 mg/day or indometh-
acin 75–150 mg/day) are usually prescribed to control chest pain,
while corticosteroids are prescribed as a second choice in cases
of contraindication, intolerance or failure of aspirin/NSAIDs.66 In
the setting of myopericarditis, some authors recommend reducing
dosages, as compared with pure pericarditis, because in animal mod-
els of myocarditis, NSAIDs have been shown to be non-efficacious
and may enhance inflammation, increasing mortality.69,70,72,73
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However, the application of these findings from animal models to
humans may be questionable.66 In addition, there are insufficient
data to recommend the use of colchicine, which is a well-established
adjunctive treatment for acute and recurrent pericarditis.58 Despite
the lack of specific therapies for most cases, several non-specific re-
commendations are important. Rest and avoidance of physical activ-
ity beyond normal sedentary activities is recommended in all
patients with myopericarditis.53,54,66
Sudden cardiac death cases have been reported in military per-
sonnel after strenuous exertion and also in male athletes without
prodromic symptoms [football (soccer) players, swimming].53,54,66
While in isolated pericarditis, return to exercise is permissible
when there is no further evidence of active disease in non-athletes,
or after 3 months in athletes, the presence or suspicion of myocar-
dial involvement leads to contraindication of physical exercise for at
least 6 months from the onset of the illness according to expert
opinion and previous recommendations for participation in com-
petitive sports.53,54,66
3.4.3 Prognosis
Myocardial involvement in pericarditis has a good prognosis,
and several observational series have demonstrated no
evolution to heart failure or mortality in patients with myo-
pericarditis.34,66– 68,70,71
Recommendations for the diagnosis and management
of pericarditis associated with myocarditis
Recommendations Classa Levelb Ref.c
In cases of pericarditis with suspected
associated myocarditis, coronary
angiography (according to clinical
presentation and risk factor assessment)
is recommended in order to rule out
acute coronary syndromes
I C
Cardiac magnetic resonance is
recommended for the confirmation of
myocardial involvement
I C
Hospitalization is recommended for
diagnosis and monitoring in patients with
myocardial involvement
I C
Rest and avoidance of physical activity
beyond normal sedentary activities is
recommended in non-athletes and
athletes with myopericarditis for a
period of 6 months
I C
Empirical anti-inflammatory therapies
(lowest efficacious doses) should be
considered to control chest pain
IIa C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.5 Pericardial effusion
The normal pericardial sac contains 10–50 ml of pericardial fluid as
a plasma ultrafiltrate that acts as a lubricant between the pericardial
layers. Any pathological process usually causes an inflammation with
the possibility of increased production of pericardial fluid (exudate).
An alternative mechanism of accumulation of pericardial fluid may
be decreased reabsorption due to a general increase in systemic
venous pressure as a result of congestive heart failure or pulmonary
hypertension (transudate).48 Pericardial effusion may be classified
according to its onset (acute or subacute vs. chronic when lasting
.3 months), distribution (circumferential or loculated), haemo-
dynamic impact (none, cardiac tamponade, effusive-constrictive),
composition (exudate, transudate, blood, rarely air, or gas from bac-
terial infections) and, in particular, by its size (Table 8) based on a
simple semiquantitative echocardiographic assessment as mild
(,10 mm), moderate (10–20 mm) or large (.20 mm) (Web Fig-
ure 2).48 This semiquantitative assessment has also proven to be use-
ful in estimating the risk of specific aetiology and complications
during follow-up in the setting of pericarditis.9,48,51 In the last
20 years, five major surveys have been published on the character-
istics of moderate to large pericardial effusions (Web Table 3).74–78
A significant proportion of patients with pericardial effusion are
asymptomatic and pericardial effusion constitutes an incidental
and unexpected finding on X-ray or echocardiogram performed
for other reasons. According to these series, many cases remain
idiopathic in developed countries (up to 50%), while other common
causes include cancer (10–25%), infections (15–30%), iatrogenic
causes (15–20%) and connective tissue diseases (5–15%), whereas
TB is the dominant cause in developing countries (.60%), where
TB is endemic.52,79 In the setting of pericarditis with pericardial ef-
fusion, the prevalence of malignant or infectious aetiologies ranges
from 15 to 50% depending on the published series.6,9
3.5.1 Clinical presentation and diagnosis
The clinical presentation of pericardial effusion varies according to
the speed of pericardial fluid accumulation. If pericardial fluid is rap-
idly accumulating, such as after wounds or iatrogenic perforations,
the evolution is dramatic and even small amounts of blood may
cause an increase in intrapericardial pressure within minutes and
overt cardiac tamponade. On the other hand, a slow accumulation
of pericardial fluid allows the collection of a large effusion in days to
weeks before a significant increase in pericardial pressure causes
symptoms and signs (Web Figure 3).48,80,81
Classic symptoms include dyspnoea on exertion progressing to
orthopnoea, chest pain and/or fullness. Additional occasional
Table 8 Classification of pericardial effusion
Onset Acute
Subacute
Chronic (>3 months)
Size Mild <10 mm
Moderate 10–20mm
Large >20 mm
Distribution Circumferential
Loculated
Composition Transudate
Exudate
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symptoms due to local compression may include nausea (dia-
phragm), dysphagia (oesophagus), hoarseness (recurrent laryngeal
nerve) and hiccups (phrenic nerve). Non-specific symptoms include
cough, weakness, fatigue, anorexia and palpitations, and reflect
the compressive effect of the pericardial fluid on contiguous
anatomic structures or reduced blood pressure and secondary sinus
tachycardia.82–84 Fever is a non-specific sign that may be associated
with pericarditis, either infectious or immune mediated (i.e. systemic
inflammatory diseases).45
Physical examination may be absolutely normal in patients with-
out haemodynamic compromise. When tamponade develops, clas-
sic signs include neck vein distension with elevated jugular venous
pressure at bedside examination, pulsus paradoxus and diminished
heart sounds on cardiac auscultation in cases of moderate to large
effusions.82 – 84 Pericardial friction rubs are rarely heard; they can
usually be detected in patients with concomitant pericarditis.8
The diagnosis of pericardial effusion is generally performed by
echocardiography, which also enables semiquantitative assessment
of the pericardial effusion size and its haemodynamic effects. Al-
though echocardiography remains the primary diagnostic tool for
the study of pericardial diseases because of its widespread availabil-
ity, portability and limited costs, CT and CMR provide a larger field
of view, allowing the detection of loculated pericardial effusion and
pericardial thickening and masses, as well as associated chest
abnormalities.2,3,84
Recommendations for the diagnosis of pericardial
effusion
Recommendations Classa Levelb Ref.c
Transthoracic echocardiography is
recommended in all patients with
suspected pericardial effusion
I C
Chest X-ray is recommended in
patients with a suspicion of pericardial
effusion or pleuropulmonary
involvement
I C
Assessment of markers of
inflammation (i.e. CRP) are
recommended in patients with
pericardial effusion
I C
CT or CMR should be considered in
suspected cases of loculated pericardial
effusion, pericardial thickening and
masses, as well as associated chest
abnormalities
IIa C
CMR ¼ cardiac magnetic resonance; CRP ¼ C-reactive protein; CT ¼
computed tomography.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.5.2 Triage and management
When a pericardial effusion is detected, the first step is to assess its
size, haemodynamic importance (especially the presence of cardiac
tamponade) and possible associated diseases (either cardiovascular
or systemic diseases). Pericardial effusion is often associated with
known or unknown (e.g. hypothyroidism) medical conditions (up
to 60% of cases).48,75,82 If inflammatory signs are present, the clinical
management should be that of pericarditis. Cardiac tamponade
without inflammatory signs is associated with a higher risk of a neo-
plastic aetiology (likelihood ratio 2.9), whereas a severe effusion
without cardiac tamponade and inflammatory signs is usually asso-
ciated with a chronic idiopathic aetiology (likelihood ratio 20).75
A practical routine evaluation for triage of pericardial effusion is
presented in Figure 3.48,82
Recommendations for the initial management of
pericardial effusion
Recommendations Classa Levelb Ref.c
Admission is recommended for
high-risk patients with pericardial
effusiond
I C
A triage of patients with pericardial
effusion is recommended as in
Figure 3
I C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dSimilar risk criteria as for pericarditis (see Figure 1).
In chronic effusion with no definite aetiology, there are no data on
non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and
corticosteroids. If markers of inflammation are elevated, a trial
of NSAIDs and/or colchicine and/or low-dose corticosteroids
may be tried.
3.5.3 Therapy
Therapy of pericardial effusion should be targeted at the aetiology as
much as possible. In about 60% of cases, the effusion is associated
with a known disease and the essential treatment is that of the
underlying disease.48,75,82 When pericardial effusion is associated
with pericarditis, management should follow that of pericarditis.
When a pericardial effusion becomes symptomatic without evi-
dence of inflammation or when empiric anti-inflammatory drugs
are not successful, drainage of the effusion should be considered.
Pericardiocentesis with prolonged pericardial drainage of up to 30
ml/24 h may be considered in order to promote adherence of peri-
cardial layers and prevent further accumulation of fluid; however,
evidence to support this indication is based on case reports, retro-
spective studies and expert opinion.48,82,84
Unfortunately, there are no proven effective medical therapies to
reduce an isolated effusion. In the absence of inflammation, NSAIDs,
colchicine and corticosteroids are generally not effective.82,85 Peri-
cardiocentesis alone may be necessary for the resolution of large ef-
fusions, but recurrences are also common, and pericardiectomy or
less invasive options (i.e. pericardial window) should be considered
whenever fluid reaccumulates, becomes loculated or biopsy mater-
ial is required.48
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Recommendations for the therapy of pericardial
effusion
Recommendations Classa Levelb Ref.c
It is recommended to target the
therapy of pericardial effusion at the
aetiology
I C
Aspirin/NSAIDs/colchicine and
treatment of pericarditis is
recommended when pericardial effusion
is associated with systemic inflammation
I C
Pericardiocentesis or cardiac surgery is
indicated for cardiac tamponade or for
symptomatic moderate to large
pericardial effusions not responsive to
medical therapy, and for suspicion of
unknown bacterial or neoplastic
aetiology
I C
NSAIDs ¼ non-steroidal anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.5.4 Prognosis and follow-up
The prognosis of pericardial effusion is essentially related to the aeti-
ology.48,82,86 The size of the effusion is correlated with the progno-
sis, as moderate to large effusions are more common for specific
aetiologies such as bacterial and neoplastic conditions.9,48 Idiopathic
pericardial effusion and pericarditis have an overall good prognosis
with a very low risk of complications, especially if the effusion is mild
to moderate. In contrast with these observations, a recently pub-
lished prospective study has shown that even with mild pericardial
effusion the overall prognosis may be worse than in age- and sex-
matched controls.87
Large idiopathic chronic effusions (.3 months) have a 30–35%
risk of progression to cardiac tamponade.88 Also, subacute (4–6
weeks) large effusions not responsive to conventional therapy and
with echocardiographic signs of collapse of the right chambers
may have an increased risk of progression according to some
authors, who recommend preventive drainage in such cases.89
Documented idiopathic pericarditis has a very low risk of constrict-
ive pericarditis despite several recurrences: here the risk is related
to the aetiology and not the number of recurrences.36 The follow-
up of pericardial effusion is mainly based on the evaluation of symp-
toms and the echocardiographic size of the effusion, as well as
additional features such as inflammatory markers (i.e. CRP).48
Cardiac tamponade or
suspected bacterial or
neoplastic aetiology?
Pericardiocentesis and
aetiology search
Elevated inflammatory
markers?
Empiric ant-inflammatory
therapy (treat as pericarditis)
Known associated
disease?
Pericardial effusion
probably related.
Treat the disease.
Large (>20 mm)
pericardial effusion?
Follow-up
Consider pericardiocentesis
and drainage 
if chronic (>3 months)
Yes No
Yes No
Yes No
Yes
No
Figure 3 A simplified algorithm for pericardial effusion triage and management.
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A mild idiopathic effusion (,10 mm) is usually asymptomatic,
generally has a good prognosis and does not require specific mon-
itoring.48 Moderate to large effusions (.10 mm) may worsen, and
especially severe effusions may evolve towards cardiac tamponade
in up to one-third of cases. For idiopathic moderate effusions, an
appropriate timing for echocardiographic follow-up may be an
echocardiogram every 6 months. For a severe effusion, an echocar-
diographic follow-up may be every 3–6 months. A tailored follow-
up is also warranted considering the relative stability or evolution of
the size.48 Specific considerations on pericardial effusion in the post-
operative setting are discussed in the section on post-cardiac injury
syndromes (section 5.5).
3.6 Cardiac tamponade
Cardiac tamponade is a life-threatening, slow or rapid compression
of the heart due to the pericardial accumulation of fluid, pus, blood,
clots or gas as a result of inflammation, trauma, rupture of the heart
or aortic dissection.81,84 Clinical signs in a patient with cardiac tam-
ponade include tachycardia, hypotension, pulsus paradoxus, raised
jugular venous pressure, muffled heart sounds, decreased electro-
cardiographic voltage with electrical alternans and an enlarged
cardiac silhouette on chest X-ray with slow-accumulating
effusions.81– 84 A key diagnostic finding is pulsus paradoxus (conven-
tionally defined as an inspiratory decrease in systolic arterial pres-
sure of .10 mmHg during normal breathing). Pulsus paradoxus is
due to exaggerated ventricular interdependence occurring in
cardiac tamponade, when the overall volume of cardiac chambers
becomes fixed and any change in the volume of one side of the heart
causes the opposite changes in the other side (i.e. inspiratory in-
crease of venous return and right chambers with decreased volume
of left chambers and reduced systemic blood pressure). The magni-
tude of clinical and haemodynamic abnormalities depends on the
rate of accumulation and amount of pericardial contents, the disten-
sibility of the pericardium and the filling pressures and compliance of
the cardiac chambers (Web Figure 3). Various causes for cardiac tam-
ponade are listed in Table 9.
The stiffness of the pericardium determines fluid increments pre-
cipitating tamponade, as illustrated by characteristic pericardial
pressure–volume (strain–stress) curves: there is an initial slow as-
cent, followed by an almost vertical rise (Web Figure 3). This steep
rise makes tamponade a ‘last-drop’ phenomenon: the final incre-
ment produces critical cardiac compression and the first decrement
during drainage produces the largest relative decompression.80– 84
In a patient with clinical suspicion of cardiac tamponade, several
diagnostic tools are required. An ECG may show signs of pericardi-
tis, with especially low QRS voltages and electrical alternans. Both
ECG signs are generally considered to be an expression of the
damping effect of pericardial fluid and swinging heart. Echocardiog-
raphy is the single most useful diagnostic tool to identify pericardial
effusion and estimate its size, location and degree of haemodynamic
impact. Also, echocardiography is used to guide pericardiocentesis
with excellent safety and efficacy. Signs of tamponade can be iden-
tified by echocardiography: swinging of the heart, early diastolic col-
lapse of the right ventricle, late diastolic collapse of the right atrium,
abnormal ventricular septal motion, exaggerated respiratory vari-
ability (.25%) in mitral inflow velocity, inspiratory decrease and ex-
piratory increase in pulmonary vein diastolic forward flow,
respiratory variation in ventricular chamber size, aortic outflow vel-
ocity (echocardiographic pulsus paradoxus) and inferior vena cava
plethora.2,3,82,84 CT and CMR are often less readily available and
are generally unnecessary unless Doppler echocardiography is not
feasible. Cardiac catheterization is rarely used to diagnose cardiac
tamponade. It will show equilibration of average diastolic pressure
and characteristic respiratory reciprocation of cardiac pressures,
i.e. an inspiratory increase on the right and a concomitant decrease
on the left—the proximate cause of pulsus paradoxus. Except in
low-pressure tamponade, diastolic pressures throughout the heart
are usually in the range of 15–30 mmHg.
The treatment of cardiac tamponade involves drainage of the peri-
cardial fluid, preferably by needle pericardiocentesis, with the use of
echocardiographic or fluoroscopic guidance, and should be per-
formed without delay in unstable patients. Alternatively, drainage is
performed by a surgical approach, especially in some situations
such as purulent pericarditis or in urgent situations with bleeding
into the pericardium. A triage system (Web Figure 4) has been pro-
posed by the ESC Working Group on Myocardial and Pericardial Dis-
eases in order to guide the timing of the intervention and the
possibility of transferring the patient to a referral centre.84 This triage
system is essentially based on expert consensus and requires add-
itional validation in order to be recommended in clinical practice.
Recommendations for the diagnosis and treatment of
cardiac tamponade
Recommendations Classa Levelb Ref.c
In a patient with clinical suspicion of
cardiac tamponade, echocardiography is
recommended as the first imaging
technique to evaluate the size, location
and degree of haemodynamic impact of
the pericardial effusion
I C
Urgent pericardiocentesis or cardiac
surgery is recommended to treat cardiac
tamponade
I C
Table 9 Causes of cardiac tamponade
Common causes: 
• Pericarditis
• Tuberculosis
• Iatrogenic (invasive procedure-related, post-cardiac surgery)
• Trauma
• Neoplasm/malignancy
Uncommon causes: 
• Collagen vascular diseases (systemic lupus erythematosus,   
  rheumatoid arthritis, scleroderma)
• Radiation induced
• Postmyocardial infarction
• Uraemia
• Aortic dissection
• Bacterial infection
• Pneumopericardium
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A judicious clinical evaluation including
echocardiographic findings is
recommended to guide the timing of
pericardiocentesis
I C
A triage system may be considered to
guide the timing of pericardiocentesis
(Web Figure 4)
IIb C
Vasodilators and diuretics are not
recommended in the presence of
cardiac tamponade
III C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.7 Constrictive pericarditis
Constrictive pericarditis can occur after virtually any pericardial dis-
ease process, but only rarely follows recurrent pericarditis.37 The
risk of progression is especially related to the aetiology: low
(,1%) in viral and idiopathic pericarditis, intermediate (2–5%) in
immune-mediated pericarditis and neoplastic pericardial diseases
and high (20–30%) in bacterial pericarditis, especially purulent peri-
carditis.36 A few large historical series of patients with constrictive
pericarditis have been described from tertiary referral centres
(Stanford, Mayo Clinic, Cleveland Clinic and Groote Schuur Hos-
pital) reporting cases after pericardiectomy (Web Table 4).90 – 93
The most common reported causes in developed countries were
idiopathic or viral (42–49%), post-cardiac surgery (11–37%), post-
radiation therapy (9–31%) (mostly for Hodgkin’s disease or breast
cancer), connective tissue disorder (3–7%), post-infectious causes
(TB or purulent pericarditis in 3–6%) and miscellaneous causes
(malignancy, trauma, drug-induced, asbestosis, sarcoidosis, uraemic
pericarditis in ,10%). TB is now only a rare cause of constrictive
pericarditis in developed countries, while it is a major cause in devel-
oping countries.93 However, this disorder may be increasing among
immigrants from underdeveloped nations and patients with HIV
infection.
3.7.1 Clinical presentation
Constrictive pericarditis is characterized by impaired diastolic
filling of the ventricles due to pericardial disease. The classic clin-
ical picture is characterized by signs and symptoms of right heart
failure with preserved right and left ventricular function in the ab-
sence of previous or concomitant myocardial disease or advanced
forms. Patients complain about fatigue, peripheral oedema, breath-
lessness and abdominal swelling. The delay between the initial
pericardial inflammation and the onset of constriction is variable
and is possibly a direct evolution from subacute/chronic pericardi-
tis to constrictive pericarditis.36 Venous congestion, hepatomeg-
aly, pleural effusions and ascites may occur. Haemodynamic
impairment of the patient can be additionally aggravated by a sys-
tolic dysfunction due to myocardial fibrosis or atrophy in more ad-
vanced cases.
Although classic and advanced cases show prominent pericardial
thickening and calcifications in chronic forms, constriction may also
be present with normal pericardial thickness in up to 20% of the
cases.94 Pericardiectomy is equally successful in those with and with-
out increased pericardial thickness.
3.7.2 Diagnosis
A diagnosis of constrictive pericarditis is based on the association of
signs and symptoms of right heart failure and impaired diastolic filling
due to pericardial constriction by one or more imaging methods, includ-
ing echocardiography,95 CT, CMR, and cardiac catheterization.2,3,96 The
main differential diagnosis is with restrictive cardiomyopathy (Table 10).
Recommendations for the diagnosis of constrictive
pericarditis
Recommendations Classa Levelb Ref.c
Transthoracic echocardiography is
recommended in all patients with
suspected constrictive pericarditis
I C
Chest X-ray (frontal and lateral views)
with adequate technical characteristics is
recommended in all patients with
suspected constrictive pericarditis
I C
CT and/or CMR are indicated as
second-level imaging techniques to
assess calcifications (CT), pericardial
thickness, degree and extension of
pericardial involvement
I C
Cardiac catheterization is indicated
when non-invasive diagnostic methods
do not provide a definite diagnosis of
constriction
I C
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
3.7.3 Therapy
Although the mainstay of treatment of chronic permanent cases is
surgery, medical therapy may have a role in at least three conditions.
First, medical therapy of specific aetiologies (i.e. tuberculous peri-
carditis) may be useful to prevent the progression to constriction.
Antituberculosis antibiotics may significantly reduce the risk of con-
striction from .80% to ,10%.79,97
Second, medical therapy (generally based on anti-inflammatory
drugs) may solve the transient constriction occurring in 10–20%
of cases within a few months, generally as a temporary phenomenon
during the resolution of pericarditis.51,98,99 The detection of ele-
vated CRP and imaging evidence of pericardial inflammation by con-
trast enhancement on CT and/or CMR may be helpful to identify
patients with potentially reversible forms of constriction where em-
piric anti-inflammatory therapy should be considered and may pre-
vent the need for pericardiectomy.100
Third, medical therapy is supportive and aimed at controlling
symptoms of congestion in advanced cases and when surgery is con-
traindicated or at high risk. In these cases, medical therapy should
never delay surgery, if this option is feasible, because advanced cases
have a higher mortality and a worse prognosis if surgery is delayed.51
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3.7.4 Specific forms
The classic description of chronic permanent constrictive pericardi-
tis has been challenged by specific forms of constrictive syndromes
(i.e. transient constriction, effusive-constrictive forms). Definitions,
main differential diagnoses and treatment of the main constrictive
pericardial syndromes are summarized in Table 11.51
3.7.4.1 Transient constrictive pericarditis
A temporary form of constriction usually develops with pericar-
ditis and mild effusion and resolves with anti-inflammatory
therapy within several weeks.98,99 The typical clinical course im-
plies the presence of acute inflammatory pericarditis with con-
striction due to inflammation, which resolves once the
inflammatory process is treated.98,99 Thus, in the absence of evi-
dence that the condition is chronic (e.g. cachexia, atrial fibrillation,
hepatic dysfunction or pericardial calcification), patients with
newly diagnosed constrictive pericarditis who are haemodynam-
ically stable may be given a trial of conservative management
for 2–3 months before recommending pericardiectomy. Since
the inflamed pericardium is enhanced on CT and/or CMR,
Table 11 Definitions and therapy of main constrictive pericardial syndromes (adapted from Imazio et al.51)
Syndrome Therapy
Transient constriction (d.d. permanent constrictive 
pericarditis, restrictive CMP).
Reversible pattern of constriction following 
spontaneous recovery or medical therapy. medical therapy.
Effusive-constrictive pericarditis (d.d. cardiac 
tamponade, constrictive pericarditis).
Failure of the right atrial pressure to fall by 50% or 
to a level below 10 mmHg after pericardiocentesis. 
May be diagnosed also by non-invasive imaging.
Pericardiocentesis followed by medical therapy. 
Surgery for persistent cases.
Chronic constriction (d.d. transient constriction, 
restrictive CMP).
Persistent constriction after 3–6 months. Pericardiectomy, medical therapy for advanced 
cases or high risk of surgery or mixed forms with 
myocardial involvement.
CMP ¼ cardiomyopathy; d.d. ¼ differential diagnosis.
Table 10 Constrictive pericarditis vs. restrictive cardiomyopathy: a brief overview of features for the differential
diagnosis (Modified from Imazio et al.51)
Diagnostic 
evaluation
Constrictive pericarditis Restrictive cardiomyopathy
Regurgitant murmur, Kussmaul sign may be present, S3 
(advanced).
ECG Low voltages, pseudoinfarction, possible widening of QRS, 
Echocardiography • Septal bounce. 
• P
• Respiratory variation of the mitral peak E velocity of >25% 
 and variation in the pulmonar
• w propagation velocity (Vp) >45 cm/sec.
• Tissue Doppler: peak e' >8.0 cm/s.
• Small left ventricle with large atria, possible increased wall  
 thickness.
• E/A ratio >2, short DT.
• 
• w propagation velocity (Vp) <45 cm/sec.
• Tissue Doppler: peak e' <8.0 cm/s.
Cardiac 
Catheterization
‘Dip and plateau’ or ‘square root’ sign, right ventricular diastolic, and left 
ventricular diastolic pressures usually equal, ventricular interdependence 
(i.e. assessed by the systolic area index >1.1).a
Marked right ventricular systolic hypertension 
(>50 mmHg) and left ventricular diastolic pressure exceeds 
right ventricular diastolic pressure (LVEDP >RVEDP)
 at rest or during exercise by 5 mmHg or more 
(RVEDP <1/3 RVSP).
CT/CMR
interdependence (real-time cine CMR).
Normal pericardial thickness (<3.0 mm), myocardial 
involvement by morphology and functional study (CMR).
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography; DT¼ deceleration time; ECG ¼ electrocardiogram; LVEDP ¼ left ventricular end-diastolic pressure;
RVEDP¼ right ventricular end-diastolic pressure; RVSP ¼ right ventricular systolic pressure; S3 ¼ third sound. Kussmaul sign is a paradoxical rise in jugular venous pressure on
inspiration.
aThe systolic area index was defined as the ratio of the RV area (mmHg x s) to the LV area (mmHg x s) in inspiration versus expiration.96
Specific diagnostic echocardiographic criteria for the diagnosis of constrictive pericarditis has been recently proposed by the Mayo Clinic and include: septal bounce or ventricular
septal shift with either medial e′ .8 cm/s or hepatic vein expiratory diastolic reversal ratio .0.78 (sensitivity 87%, specificity 91%; specificity may increase to 97% if all criteria are
present with a correspondent decrease of sensitivity to 64%.95
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multimodality imaging with CT and CMR may be helpful to detect
pericardial inflammation.2,3,100
3.7.4.2 Effusive-constrictive pericarditis
The pericardial cavity is typically obliterated in patients with
constrictive pericarditis. Thus even the normal amount of peri-
cardial fluid is absent. However, pericardial effusion may be pre-
sent in some cases. In this setting, the scarred pericardium not
only constricts the cardiac volume, but can also put pericardial
fluid under increased pressure, leading to signs suggestive of car-
diac tamponade. This combination is called effusive-constrictive
pericarditis.101
Effusive-constrictive pericarditis appears to be relatively uncom-
mon in developing countries, with only limited published data.101
Most cases of effusive-constrictive pericarditis in developed coun-
tries are idiopathic, reflecting the frequency of idiopathic pericar-
dial disease in general. However, TB is the most common cause in
developing countries.102 Other reported causes include radiation,
neoplasia, chemotherapy, infection (especially TB and purulent
forms) and post-surgical pericardial disease.102
Patients with effusive-constrictive pericarditis usually have clin-
ical features of pericardial effusion or constrictive pericarditis, or
both. The diagnosis of effusive-constrictive pericarditis often
becomes apparent during pericardiocentesis in patients initially
considered to have uncomplicated cardiac tamponade.101 For
these reasons, it is recommended that intrapericardial pressures,
right heart pressures and systemic arterial blood pressure are
monitored during elective pericardiocentesis whenever possible.
A persistently elevated right atrial pressure after efficient peri-
cardiocentesis may also be due to right heart failure or tricuspid
regurgitation.
However, non-invasive imaging may be equally useful for the diag-
nosis of effusive-constrictive pericarditis.102 The epicardial layer of
pericardium, which is responsible for the constrictive component
of this process, is not typically thickened to a degree that is detect-
able on imaging studies. Nevertheless, careful detection of Doppler
findings of constriction can be reported following pericardiocen-
tesis for cardiac tamponade, and effusive-constrictive pericarditis
can also be suspected in these cases without haemodynamic mon-
itoring. Useful data may also be provided by CMR. The utility of
CMR in constrictive pericardial disease is well established, providing
the opportunity not only to evaluate pericardial thickness, cardiac
morphology and function, but also for imaging intrathoracic cavity
structures, allowing the differentiation of constrictive pericarditis
from restrictive cardiomyopathy. Assessment of ventricular coup-
ling with real-time cine magnetic resonance during free breathing al-
lows an accurate evaluation of ventricular interdependence and
septal bounce.2,3
Since it is the visceral layer of pericardium and not the parietal
layer that constricts the heart, visceral pericardiectomy must be
performed. However, the visceral component of the pericardiect-
omy is often difficult, requiring sharp dissection of many small frag-
ments until an improvement in ventricular motion is observed. Thus
pericardiectomy for effusive-constrictive pericarditis should be per-
formed only at centres with experience in pericardiectomy for con-
strictive pericarditis.101
3.7.4.3 Chronic constrictive pericarditis
Pericardiectomy is the accepted standard of treatment in patients
with chronic constrictive pericarditis who have persistent and
prominent symptoms such as NYHA class III or IV. However, sur-
gery should be considered cautiously in patients with either mild
or very advanced disease and in those with radiation-induced con-
striction, myocardial dysfunction or significant renal dysfunction.
Surgical removal of the pericardium has a significant operative mor-
tality ranging from 6 to 12%.103 – 105 Pericardiectomy must be as
complete as is technically feasible and should be performed by ex-
perienced surgeons. Referral to a centre with a special interest in
pericardial disease may be warranted in centres with limited experi-
ence in this surgery.
Patients with ‘end-stage’ constrictive pericarditis derive little or
no benefit from pericardiectomy, and the operative risk is inordin-
ately high. Manifestations of end-stage disease include cachexia, at-
rial fibrillation, a low cardiac output (cardiac index ,1.2 l/m2/min)
at rest, hypoalbuminaemia due to protein-losing enteropathy and/or
impaired hepatic function due to chronic congestion or cardiogenic
cirrhosis.
Prior ionizing radiation is associated with a poor long-term out-
come, because it induces cardiomyopathy as well as pericardial dis-
ease. Predictors of poor overall survival are prior radiation, worse
renal function, higher pulmonary artery systolic pressure, abnormal
left ventricular systolic function, lower serum sodium level and older
age. Pericardial calcification had no impact on survival.103 – 105 Sur-
vival after radical pericardiectomy in patients with Child–Pugh
(CP) B or C (CP score ≥7) was reported to be significantly worse
than in patients with CP-A. In multivariable analysis, a CP score ≥7,
mediastinal irradiation, age and end-stage renal disease (ESRD) iden-
tified an increased risk of death after radical pericardiectomy.106 On
this basis, it seems appropriate to apply the CP scoring system for
the prediction of mortality after radical pericardiectomy in patients
with constrictive pericarditis.
Recommendations for therapy of constrictive
pericarditis
Recommendations Classa Levelb Ref.c
The mainstay of treatment of chronic
permanent constriction is
pericardiectomy
I C
Medical therapy of specific pericarditis (i.e.
tuberculous pericarditis) is recommended
to prevent the progression of constriction
I C
Empiric anti-inflammatory therapy may be
considered in cases with transient or new
diagnosis of constriction with concomitant
evidence of pericardial inflammation (i.e.
CRP elevation or pericardial enhancement
on CT/CMR)
IIb C
CMR ¼ cardiac magnetic resonance; CRP ¼ C-reactive protein; CT ¼
computed tomography.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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4. Multimodality cardiovascular
imaging and diagnostic work-up
4.1 Multimodality imaging
4.1.1 Chest X-ray
Although chest X-ray can detect pericardial calcifications, present-
ing as a curvilinear density at the extreme margin of the silhouette,
particularly on the lateral view,107 other techniques (i.e. echocardi-
ography, CT) yield much greater accuracy in assessing the heart and
lungs, providing information with regard to cardiac size and the pres-
ence of pulmonary pathology (e.g., pulmonary congestion, pneumo-
nia, TB, lung cancer), pleural effusion and hilar and mediastinal
enlargement.
4.1.2 Echocardiography
Transthoracic echocardiography is the first-line imaging test in pa-
tients with suspected pericardial disease, because it accurately de-
tects pericardial effusion and cardiac tamponade, as well as
ventricular dysfunction due to myocardial involvement.2,3 Although
patients with purely fibrinous acute pericarditis may have a normal
echocardiogram, the presence of a pericardial effusion is consistent
with acute pericarditis and is one of the criteria for its diagno-
sis.2,5,6,10,11 Echocardiography may help to differentiate acute peri-
carditis from myocardial ischaemia by excluding wall motion
abnormalities consistent with coronary flow distribution in the set-
ting of patients with acute chest pain. However, 5% of patients
with acute pericarditis and myocardial involvement may demon-
strate wall motion abnormalities.
Clinically, two-dimensional echocardiography with Doppler pro-
vides the most cost-effective way of diagnosing pericardial effusion
and assessing its haemodynamic significance.48 The size of pericar-
dial effusion on two-dimensional echocardiography is qualitatively
assessed by the end-diastolic distance of the echo-free space be-
tween the epicardium and parietal pericardium: small (,10 mm),
moderate (10–20 mm), large (.20 mm) (Web Figure 2).48
In order to allow follow-up studies, it is recommended that the
images be documented digitally and the effusion size described in
a detailed way in the echocardiographic report, including not only
the extent, but also the location of each measurement. However,
the haemodynamic tolerance is more related to the rapidity of ap-
pearance of the effusion than to its total volume.48,80
Loculated pericardial effusions or pericardial effusions that con-
tain clots (e.g. after cardiac surgery) may be difficult to diagnose
using a transthoracic approach and may require transoesophageal
echocardiography.3,4 Specific findings in pericardial syndromes are
discussed in the pertinent paragraphs.
4.1.3 Computed tomography
CT should be regarded as a valuable complementary imaging modal-
ity to echocardiography.3,4,41,108,109 CT is the most accurate tech-
nique to image calcified tissue.2,3 Current multidetector CT
scanners combine acquisition speed, high contrast and spatial reso-
lution with volumetric scanning to provide excellent anatomical de-
tail of the heart and pericardium. The anatomical region of interest
covered by CT can be limited to the heart and pericardium (‘cardiac
CT’), although in patients with neoplastic, inflammatory or aortic
disease it may encompass the chest entirely and possibly also include
the abdomen and pelvis.108,109 Low-radiation cardiac CT is feasible
using prospective electrocardiographic triggering.108,109 Although
the functional consequences of pericardial disease on the heart
can be evaluated by CT—at the expense of significantly higher radi-
ation doses—echocardiography and CMR are more appropriate for
assessing this feature. Intravenous administration of iodinated con-
trast material is recommended to increase the density of blood
and to depict pericardial inflammation. The normal pericardium is
visible as a thin curvilinear structure surrounded by the hypodense
mediastinal and epicardial fat, and has a thickness ranging from 0.7 to
2.0 mm. The pericardial sinuses and their respective recesses are
visible, in particular when they contain small amounts of pericardial
fluid. The main CT findings in pericardial effusion and pericarditis are
summarized in Table 12.41,108,109
In patients with neoplastic disease, pericardial involvement may
occur by direct tumour invasion or metastatic spread. CT is import-
ant in treatment planning and patient follow-up. The diagnosis of
(congenital) pericardial cysts—presenting as well-defined, fluid-
dense structures along the left or right heart border—as well as
the differential diagnosis with other cystic structures, such as bron-
chogenic or duplication cysts, is usually straightforward. Finally, CT
can be helpful to establish the diagnosis in congenital absence of the
pericardium by showing displacement of cardiac structures through
the pericardial defect. CT is also essential in the preoperative work-
up of some patients with constrictive pericarditis, especially to de-
pict the extension of calcifications and for those with a history of
prior cardiothoracic surgery.109
4.1.4 Cardiac magnetic resonance
Over the years, CMR has shifted from a morphologic imaging mo-
dality towards a comprehensive one, allowing visualization and tis-
sue characterization of the pericardium (and heart) in patients
with pericardial disease and appraisal of the consequences of peri-
cardial abnormalities on cardiac function and filling patterns.110,111
As such, it is probably the preferred imaging modality to optimally
assess pericardial disease.112,113 Cardiac and pericardial morph-
ology are evaluated by dark-blood T1-weighted fast spin-echo and
bright-blood cine steady-state free-precession (SSFP) imaging.
Cine SSFP imaging has become the reference sequence to assess
and quantify cardiac volumes, myocardial mass and ventricular func-
tion. When acquired in real-time, this sequence can be used to as-
sess ventricular coupling by assessing the changes in ventricular
septal shape and motion over the respiratory cycle.109,110 Tissue
characterization of the heart and pericardium is achieved by dark-
blood T1-weighted and dark-blood T2-weighted, short-tau
inversion-recovery (STIR) spin-echo imaging, cine SSFP imaging
and T1-weighted contrast-enhanced and/or late contrast-enhanced
(LCE) imaging following intravenous administration of paramagnetic
gadolinium chelates.3,4,114 The LCE sequence uses an inversion-
recovery pre-pulse to increase image contrast and is well suited
to visualize pericardial inflammation.114,115
Ventricular inflow and venous flow patterns can be evaluated
using phase contrast imaging.111 Similar to CT, the normal
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Table 12 Diagnostic contribution of the different imaging modalities in various pericardial diseases
Echocardiography Computerized tomography Cardiac magnetic resonance
Acute
pericarditis
- veral patients
- thick
- variable amount of pericar
- wall motion abnormalities in myo-pericarditis
- thickened pericardial layers enhancing after contrast 
 administration
- abnormalities involving entire pericardium
- variable amount of pericar
- thickened pericardial layers
- strong pericardial LGE following contrast 
 administration
- variable amount of pericar
- (subepicardial/mid-wall) myocardial LGE 
 in cases of myopericarditis.
- inspirator
 on real-time cine CMR, due to 
 decreased pericardial compliance
Recurrent 
pericarditis
- ditis - ditis
- possibl
 adhesions
- ir
- ditis
- possibly heterogeneous distribution due 
 otic adhesions.
- ir
 deformation)
Constrictive 
pericarditis
- thick
- ± ascites
- dilated atria
- inspiratory ventricular septal motion toward left 
 ventricle (septal bounce) best documented with 
 M-mode
- marked dilation and absent or diminished 
 collapse of the IVC and hepatic veins 
- premature opening of the pulmonary valve
- r
 
- w velocity and 
 >40 % incr
 beat after inspiration;
- opposite changes during expiration; 
- normal or increased propagation velocity of 
 earl  
 M-mode
- decreased expiratory diastolic hepatic vein 
 velocities with large reversals
- normal or increased mitral annular 
 velocity (>7 cm/sec) at tissue Doppler
- annulus reversus (e’ septal >e’ lateral)
- thickened pericardial layers ± pericardial 
 
- thickening may be mild to moderate
- abnormalities usually most pronounced at the 
 base of the ventricles (RV>LV), atrioventricular 
 grooves and atria
- 
 adjacent myocardium
- compression of cardiac contents by rigid, 
 deformed pericardium
- abnormal shape of ventricular septum
- dilated atria, caval/hepatic veins
 hepatic congestion
- contrast reversal in caval/hepatic veins
- ± ascites
- atypical presentations
  *focal constrictive forms
  *effusive-constrictive forms
- thickened pericardial layers 
- pericar
- thickening may be mild to moderate
- abnormalities usually most pronounced 
 at the base of the ventricles (RV>LV), 
 atrioventricular grooves and atria
- pericar
 
- possibl
 adjacent myocardium
- compression of cardiac contents by rigid, 
 deformed pericardium
- dilated atria, caval/hepatic veins
- ± ascites
- increased ventricular coupling assessed 
 by real-time cine CMR and/or real-time 
 phase-contrast imaging
- otic adhesion of pericardial layers on 
 CMR tagging
- atypical presentations
  *focal constrictive forms
  *effusive-constrictive forms
Pericardial
effusion
- ulation in pericardial sac and/or 
 pericardial sinuses
- pericardial echolucent space throughout 
 cardiac cycle
- 
- semi-quantitative assessment of effusion 
 severity
- ulation in pericardial sac and/or 
 pericardial sinuses
- pericardial width >4 mm regarded as abnormal 
 
- advantageous to depict focal effusions and to 
 pr
- atten
 yield inf
  *simple effusion: 0–20 HU
  *proteinaceous/haemorrhagic: >20 HU
  *if very high HU, suspect intrapericardial leakage 
    of contrast (e.g. ruptured aortic dissection)
  *chylopericardium: negative HU values
  *pneumopericar
    center settings)
- pericardial layers have normal thickness, 
  *if thickened and enhancing: suspect        
  
  *if thick
       pericarditis
- may be associated with pericardial tamponade
- CT of the heart may be part of a more extended 
 examination including the remainder of the chest
 ± abdomen
- ulation in pericardial sac and/
 or pericardial sinuses
- pericardial width >4 mm regarded as 
 
- advantageous to depict focal effusions 
 and to precisely quantitate the amount 
 
- combination of sequences with different 
 ‘weighting’ yield information with regard 
 to the nature of the effusion
- pericardial layers have normal thickness, 
  *if thickened and enhancing suspect 
  
- advantageous to evaluate the remainder 
 of the heart:
  *myocardial tissue characterisation 
    (oedema,   
  osis)
  *myocardial/valvular function
  w patterns
- may be associated with pericardial 
 tamponade
Cardiac 
tamponade
- semi-quantitative assessment of effusion severity
- 
- assessment of its haemodynamic impact
- guide and monitoring pericardiocentesis
- re-evaluation for timing catheter removal
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography; HU ¼ Hounsfield units; IVC ¼ inferior vena cava; LGE¼ late gadolinium enhancement; LV ¼ left ventricle;
RV ¼ right ventricle.
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pericardium appears on T1-weighted imaging as a thin hypointense
(‘dark’) curvilinear structure surrounded by hyperintense (‘bright’)
mediastinal and epicardial fat. Normal pericardial thickness ranges
from 1.2 to 1.7 mm. The imaging characteristics of pericardial effu-
sion and pericarditis at CMR are shown in Table 12. It should be em-
phasized that CMR can accurately distinguish between mixed
myopericardial diseases such as mixed inflammatory forms (e.g.
myopericarditis or perimyocarditis) and post-myocardial infarction
pericardial injury.116,117 In patients with constrictive pericarditis,
CMR is particularly important in the diagnosis of atypical presenta-
tions, such as those with minimally thickened pericardium or
effusive-constrictive pericarditis, and those with potentially revers-
ible or transient forms of constrictive pericarditis, showing enhance-
ment of the pericardial layers at LCE imaging.115,118,119 Compared
with CT, CMR has the advantage of providing information with re-
gard to the haemodynamic consequences of the non-compliant
pericardium on cardiac filling,109 – 111 and has the potential of show-
ing fibrotic fusion of pericardial layers.120
In patients with congenital pericardial pathology and pericardial
malignancy, CMR shares the advantages of CT, but allows better tis-
sue characterization and the possibility of evaluating the functional
consequences.121 Moreover, novel techniques, such as diffusion-
weighted and dynamic contrast-enhanced magnetic resonance
imaging, open perspectives for improved tissue characterization in
patients with pericardial tumours.122
4.1.5 Nuclear medicine
In selected cases, positron emission tomography (PET) alone, or
preferably in combination with CT (PET/CT), can be indicated to
depict the metabolic activity of pericardial disease. Pericardial up-
take of 18F-fluorodeoxyglucose (FDG) tracer in patients with solid
cancers and lymphoma is indicative of (malignant) pericardial in-
volvement, thus providing essential information on the diagnosis,
staging and assessment of the therapeutic response.123 The uptake
is usually intense and often associated with a focal soft tissue
mass.124 PET/CT is also of value in identifying the nature of inflam-
matory pericarditis. In particular, tuberculous pericarditis yields
higher FDG uptakes than idiopathic forms.125 However, differenti-
ation between benign and malignant pericardial disease, as well as
differentiation between physiological and pathological cardiac
FDG uptake by PET/CT, remains challenging.123
4.1.6 Cardiac catheterization
Cardiac catheterization is not routinely used for the diagnosis of
pericardial disease, as current non-invasive techniques are usually
able to solve the differential diagnosis of a patient with the suspicion
of heart disease involving the pericardium. However, right heart
catheterization may be useful in certain circumstances. Early recog-
nition of abnormal haemodynamics related to cardiac tamponade
during invasive procedures (i.e. epicardial ablation, percutaneous
aortic valve implantation, complex angioplasty or complex proce-
dures involving trans-septal punctures, among others) may help
avoid serious consequences for the patient. In addition, the differen-
tiation between constrictive pericarditis and restrictive cardiomyop-
athy is sometimes difficult and may require an invasive test.
In cardiac tamponade, the right atrial pressure waveform has an
attenuated or an absent Y-descent. Absent Y-descent is secondary
to diastolic equalization of pressures in the right atrium and right
ventricle and lack of effective flow across the tricuspid valve in early
ventricular diastole. Also, equalization of mean right atrial, right ven-
tricular and pulmonary artery diastolic pressures and mean pulmon-
ary capillary wedge pressures can be present. Other haemodynamic
abnormalities include elevation of filling pressures in all four cardiac
chambers, right ventricle and left ventricle peak systolic pressures
out of phase, peak aortic pressure varying more than 10–12
mmHg and a decrease in cardiac output.126,127
The differentiation of constrictive pericarditis from restrictive
cardiomyopathy remains difficult. Visualization of the pericardium
by CT or CMR may help in detecting an abnormal pericardium.
But these tests provide anatomical information and do not necessar-
ily reflect the pathophysiological abnormality present. Also, patients
with surgically proven constrictive pericarditis may have a normal-
appearing pericardium on imaging studies. Alternatively patients
may have abnormal pericardial thickness in the absence of constric-
tion, especially after radiation therapy or prior cardiac surgery. Clas-
sically, direct measurements of pressures show M- or W-shaped
atrial pressure waveforms and ‘square root’ or ‘dip-and-plateau’
right ventricular pressure waveforms, reflecting impaired ventricular
filling. End-diastolic pressure equalization (typically within 5 mmHg)
occurs between these cardiac chambers in constrictive pericarditis
because of the fixed and limited space within the thickened and stiff
pericardium. Pulmonary artery systolic pressures are usually normal
in pericardial constriction; higher pulmonary pressures suggest a re-
strictive cardiomyopathy.126
Recently a novel haemodynamic parameter has been tested to
differentiate both entities.96 Specifically, the ratio of the right ven-
tricular to left ventricular systolic pressure–time area during inspir-
ation versus expiration (systolic area index) was used as a
measurement of enhanced ventricular interaction. In patients with
surgically documented constrictive pericarditis, during inspiration
there is an increase in the area of the right ventricular pressure curve
compared with expiration. The area of the left ventricular pressure
curve decreases during inspiration as compared with expiration. In
contrast, patients with restrictive myocardial disease documented
by endomyocardial biopsy usually present a decrease in the area
of the right ventricular pressure curve during inspiration as com-
pared with expiration. The area of the left ventricular pressure curve
is unchanged during inspiration as compared with expiration. This
systolic area index presented a 97% sensitivity and 100% predictive
accuracy for identifying patients with surgically proven constrictive
pericarditis.96
4.1.7 Multimodality imaging
Echocardiography, cardiac CT and CMR are often used as comple-
mentary imaging modalities (Table 13). The choice of one or mul-
tiple imaging modalities is driven by the clinical context or
condition of the patient. A modern approach for the management
of pericardial diseases should include the integration of different im-
aging modalities in order to improve the diagnostic accuracy and
clinical management of patients.2,3
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4.2 Proposal for a general diagnostic
work-up
In the management of pericardial syndromes, a major controversy
is the role of an extensive aetiological search and admission for
all patients with pericarditis or pericardial effusion.1,4,6,51
The epidemiological background is essential to develop a rational
cost-effective management programme and the clinician should es-
pecially identify causes that require targeted therapies.4,5,51,128 –130
The approach may be different for research, when we attempt to
reduce the number of ‘idiopathic’ cases. The diagnosis of idiopathic
cases is essentially an exclusion diagnosis, supported by a typical
clinical course.
On this basis, auscultation, ECG, echocardiography, chest X-ray,
routine blood tests, including markers of inflammation (i.e.,
CRP and/or ESR) and myocardial lesions (CK, troponins), are
recommended in all cases of suspected pericarditis. Additional
testing should be related to the suspected origin and clinical
presentation.5,6,128 – 130
The major specific causes to be ruled out are bacterial pericar-
ditis (especially TB), neoplastic pericarditis and pericarditis asso-
ciated with a systemic disease (generally an autoimmune disease)
(Web Table 5).9,77,129 – 131 Each of these specific causes has a
frequency of 5% of all unselected cases of pericarditis from
developed countries (Web Table 5),9,77,129 – 131 while frequencies
increase in moderate to large pericardial effusions (Web
Table 3).8,74 – 78 Emerging additional causes include iatrogenic
ones (percutaneous coronary interventions, pacemaker insertion,
catheter ablation).132 The aetiological spectrum is different in
developing countries with a high prevalence of TB (e.g. 70–80%
of pericarditis in sub-Saharan Africa, and often associated with
HIV infection).52,79
Certain clinical features at presentation may be associated with
an increased risk of specific aetiologies (non-viral or non-
idiopathic) and complications during follow-up (recurrences,
tamponade, constriction) and are suggested as ‘high-risk features’
useful for the triage of pericarditis to establish the need for a full
aetiological search and admission in a single patient (Figure 1, Web
Table 6).8,9 Factors indicated as ‘major’ have been validated by
multivariate analysis, while factors indicated as ‘minor’ are based
on expert opinion and literature review:9 they are essentially the-
oretical risk factors for complications and suggest the indication
for admission and close monitoring of the evolution. Major risk
factors include fever .388C [hazard ratio (HR) 3.56], subacute
course (symptoms developing over several days or weeks; HR
3.97), large pericardial effusion (diastolic echo-free space
.20 mm in width) or cardiac tamponade (HR 2.15) and failure
of aspirin or NSAIDs (HR 2.50).9 Large effusion and tamponade
(HR 2.51) and aspirin or NSAIDs failure (HR 5.50) also identify
an increased risk of complications during follow-up (recurrences,
tamponade, constriction).9 Minor risk factors are pericarditis as-
sociated with myocarditis, immunodepression, trauma and oral
anticoagulant therapy.
For patients with predictors of poor prognosis, major or min-
or (Figure 1), hospitalization and a full aetiological search are
warranted.5,6,8,9,128 In contrast, when these negative predictors
are absent, patients are at low risk of specific causes and com-
plications, and outpatient management may be considered.8 This
approach is safe without an excess of complications and new
unexpected diagnoses requiring a specific therapy.8,9,128 The
Table 13 Comparison of non-invasive imaging
modalities to study the pericardium
TTE CT CMR
Technical aspects
Availability +++ ++ +
Cost Low Moderate High
Exam duration (minutes) 15–30 10 30–40
Safety +++ +a ++b
Pt access and monitoring +++ ++ +/-
Pericardium
Pericardial thickness +/- +++ +++
+ +++ -
+/- ++ +++
Motion layers (adhesions) ++ + +++
Effusion detection ++ +++ +++
Effusion characterization + ++ ++
Pericardial masses + +/++ ++/+++
Guiding/monitoring 
pericardiocentesis   
+++ - -
Cardiac morphology
(Including tissue 
characterization)
++ ++ +++
Cardiac function
Systolic +++ ++c +++
Diastolic function +++ - ++
Septal motion (coupling) +++ +/- +++
Respiratory changes ++ +/- ++
CMR ¼ cardiac magnetic resonance magnetic resonance; CT ¼ computed
tomography; ECG ¼ electrocardiogram; TTE ¼ transthoracic echocardiography.
(-) not possible or poor; (+) moderate; (++) good; (+++) excellent.
aIonizing radiation, potential nephrotoxicity of contrast medium, allergic reactions
to contrast.
bPatients with metallic implants, claustrophobia, potential nephrotoxicity of
contrast medium, allergic reactions to contrast, restricted only to
haemodynamically stable patients.
cUse of ECG synchronized data acquisition.
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same approach is also useful for patients with recurrences who
may generally be treated as outpatients, unless predictors of
poor prognosis are present or a specific cause can be ruled
out. With a clear diagnosis of idiopathic origin and a recurrence
course with complete symptom-free periods between the epi-
sodes, it is also unnecessary to repeat a new aetiological search
at each recurrence unless new clinical features become evident.
First- and second-line general investigations are reported in the
recommendations and Tables 14–16.
Recommendations for the general diagnostic work-up
of pericardial diseases
Recommendations Classa Levelb Ref.c
In all cases of suspected pericardial
disease a first diagnostic evaluation is
recommended with
– auscultation
– ECG
– transthoracic echocardiography
– chest X-ray
– routine blood tests, including
markers of inflammation (i.e., CRP
and/or ESR), white blood cell count
with differential count, renal function
and liver tests and myocardial lesion
tests (CK, troponins)
I C
It is recommended to search for
independent predictors of an identifiable
and specifically treatable cause of
pericarditis (i.e. bacterial, neoplastic,
systemic inflammatory diseases). Major
factors include
– fever .388C
– subacute course (symptoms
developing over several days or
weeks)
– large pericardial effusion (diastolic
echo-free space .20 mm in width)
– cardiac tamponade
– failure of aspirin or NSAIDs
I B 8,9
CT and/or CMR are recommended as
second-level testing for diagnostic
workup in pericarditis
I C
Pericardiocentesis or surgical drainage
are indicated for cardiac tamponade or
suspected bacterial and neoplastic
pericarditis
I C
Percutaneous or surgical pericardial
biopsy may be considered in selected
cases of suspected neoplastic or
tuberculous pericarditis
IIb C
Further testing is indicated in high-risk
patients (defined as above) according to
the clinical conditions
I C
CK ¼ creatine kinase; CMR ¼ cardiac magnetic resonance; CRP ¼ C-reactive
protein; CT ¼ computed tomography; ECG ¼ electrocardiogram; ESR ¼
erythrocyte sedimentation rate; NSAIDs ¼ non-steroidal anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5. Specific aetiologies of
pericardial syndromes
5.1 Viral pericarditis
5.1.2 Definition and clinical spectrum
Most cases of acute pericarditis in developed countries are based on
viral infections or are autoreactive.5,6,133 – 135 Acute viral pericarditis
Table 14 First and second level investigations for
pericarditis
Level Investigation
1st level
(all cases) blood cell count).
Renal function and liver tests, thyroid function.
Markers of myocardial lesion (i.e. troponins, CK).
ECG
Echocardiography
Chest X-ray
2nd level
(if 1st level 
not sufficient
for diagnostic 
purposes)
CT and/or CMR
pericardiocentesis, or surgical drainage, for (i) 
cardiac tamponade or (ii) suspected bacterial, 
neoplastic pericarditis, or (iii)  symptomatic 
moderate to large effusions not responding to 
aetiologies according to clinical presentation 
(presence of high risk clinical criteria).
CK ¼ creatine kinase; CMR ¼ cardiac magnetic resonance; CRP ¼ C-reactive
protein; CT ¼ computed tomography; ECG ¼ electrocardiogram; ESR ¼
erythrocyte sedimentation rate.
Table 15 Main analyses to be performed on
pericardial fluid
Analysis Test
ratio >0.6a, blood cell count.
Cytology
centrifugation, and rapid analysis improve 
diagnostic yield).
Polymerase chain 
reaction (PCR)
PCR for TB.
Microbiology Mycobacterium cultures, aerobic and 
anaerobic cultures.
LDH ¼ lactate dehydrogenase; TB ¼ tuberculosis.
aHigh values of protein and LDH are commonly interpreted as an exudate, as in
pleural fluid, but have not been validated for pericardial fluid.
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often presents as a self-limited disease, with most patients recover-
ing without complications.5,6,9,36 However, as a consequence of
acute viral pericarditis, cardiac tamponade, recurrent pericarditis
and, more rarely, constrictive pericarditis may also develop.36
5.1.3 Pathogenesis
Cardiotropic viruses can cause pericardial and myocardial inflamma-
tion via direct cytolytic or cytotoxic effects (e.g. enteroviruses) and/
or via T and/or B cell–driven immune-mediated mechanisms (e.g.
herpesviruses). Persistence of viral nucleic acid without virus repli-
cation in the peri(myo)cardium is known to sustain ongoing inflam-
mation and effusions via (auto)immune processes directed against
specific cardiac proteins by molecular mimicry.133
5.1.4 Diagnosis
The definite diagnosis of viral pericarditis requires a comprehensive
workup of histological, cytological, immunohistological and molecu-
lar investigations in pericardial fluid and peri-/epicardial biopsies
Table 16 Suggested diagnostic flowchart in some common conditions in high risk patients
Clinical condition Blood tests Imaging a Others
Probable autoimmune 
condition
- ANA, ENA, ANCA
 (ACE  and 24 h urinary 
 calcium  
- if sarcoidosis is suspected)
- Ferritin if Still disease is 
 suspected.
Consider PET if large vessel 
arteritis (Horton or Takayasu) 
or Sarcoidosis is suspected.
Specialist consultation may 
be useful. Hypereosinophilia 
(Churg Strauss), oral and 
genital apthae (Behcet); 
difference in blood 
pressure between two 
arms (Takayasu), dry eyes 
(Sjögren, Sarcoidosis) 
macroglossia (amyloidosis).
Probable TB IGRA test (i.e Quantiferon, 
ELISpot, etc).
Chest CT Scan - Acid-fast bacilli staining,  
 mycobacterium cultures,
- PCR for genome. 
 Adenosine deaminase 
 >40 U/l, unstimulated 
 IFN-gamma.
- Culture and PCR in 
 sputum and other 
 
- Consider pericardial 
 biopsy.
Probable neoplasm
in the blood when serosal 
effusions are present).
Chest and abdomen CT scan, 
consider PET.
Cytology (higher volumes of 
analysis improve diagnostic 
yield). Tumour markers 
(e.g. CEA >5 ng/ml or 
CYFRA 21–1 >100 ng/ml).
Consider pericardial biopsy.
Probable viral infections - Genome search with PCR is 
 now preferred to serology for 
 most virusesb.
- Consider serology for HCV 
 and HIV
Genome search with PCR 
agents, e.g. enteroviruses, 
adenoviruses, parvovirus 
B19, HHV-6, CMV, EBVb.
Infectious specialist 
consultation in case of 
positivity.
Probable bacterial infections - Blood cultures before 
 antibiotics.
- Serology for Coxiella burnetii 
 if Q-fever is suspected.
- Serology for Borrelia spp. if 
 Lyme disease is suspected.
Chest CT scan - Aerobic and anaerobic 
 cultures.
- Glucose
Consider pericardial biopsy.
conditions (periodic fevers)    
FMF and TRAPS mutations. Possible clues for TRAPS 
are familial forms and poor 
response to colchicine.
Chronic pericardial effusion TSH. Renal function tests. Consider appropriate tests 
for suspected neoplasms 
and TB.
 Probable constriction BNP (near-normal). Cardiac MR, chest CT scan, 
biventricular catheterization.
All the tests for suspected 
TB.
ACE ¼ angiotensin-converting enzyme; ANA ¼ anti-nuclear antibodies; ANCA ¼ anti-neutrophil cytoplasm antibodies; BNP ¼ brain natriuretic peptide; CEA ¼
carcinoembryonic antigen; CMV ¼ cytomegalovirus; CT ¼ computed tomography; EBV ¼ Epstein-Barr virus; ENA ¼ anti-extractable nuclear antigens; FMF ¼ familial
Mediterranean fever; HCV ¼ hepatitis C virus; HHV ¼ human herpesvirus; HIV ¼ human immunodeficiency virus; IGRA ¼ interferon-gamma release assay; MR ¼ magnetic
resonance; PCR ¼ polymerase chain reaction; PET ¼ positron emission tomography; spp ¼ species; TB ¼ tuberculosis; TRAPS ¼ tumour necrosis factor receptor-associated
periodic syndrome; TSH ¼ thyroid stimulating hormone.
aConsider storage of a sterile sample for further analyses.
bSee viral pericarditis section—at present, these investigations have no therapeutic or prognostic implications.
IGRAs are whole-blood tests that can aid in diagnosing Mycobacterium tuberculosis infection. They do not help to differentiate latent TB infection from TB disease.
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obtained in conjunction with pericardioscopy, permitting the evalu-
ation of possible algorithms for a causative therapy.133 In contrast,
serological tests were found to be futile in the diagnosis of viral peri-
carditis. Whereas no up-regulation of pro-inflammatory cytokine
expression is noted in the serum, TNF-a, vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF), IL-6,
IL-8 and interferon-gamma (IFN-g) are increased in the pericardial
effusions of patients with pericarditis, indicating the presence of lo-
cal inflammatory reactions.134,135 Accordingly, there is no correl-
ation of antiviral antibodies in the serum or virus isolation from
throat or rectal swabs with positive molecular polymerase chain re-
action (PCR)/in situ hybridization analyses for the detection of car-
diotropic viruses in pericardial tissue and fluid.136
5.1.5 Identification of viral nucleic acids
Mainly by quantitative PCR techniques, nucleic acids of different
cardiotropic RNA and DNA viruses have been detected in
epicardial and pericardial biopsies and the pericardial fluid of chil-
dren and adults with acute pericarditis, but also in patients with re-
curring and constrictive pericarditis.133,137 Regarding RNA
viruses, various subtypes of enteroviruses including echoviruses
and coxsackieviruses of groups A (A4, A16) and B (CVB2,
CVB3, CVB4) were identified in patients with acute and constrict-
ive pericarditis.137,138 Among the RNA viruses, influenza A viruses
(e.g. H1N1, H5N1, H3N2) and occasionally chikungunya virus, hu-
man coronavirus NL-63, respiratory syncytial virus and dengue
virus infections were suspected as aetiopathogenic agents in
pericarditis.
Compared with RNA viruses, nucleic acids of DNA viruses, in-
cluding parvovirus B19 and herpesviruses [Epstein–Barr virus
(EBV) and human herpesvirus 6 (HHV-6)], are present in pericardial
biopsies and pericardial fluid at greater frequencies and higher viral
DNA copy numbers.133 Whereas parvovirus B19, with up to 7 ×
106 GE/lg DNA was predominantly detected in epicardial tissue,
EBV was most frequently found in pericardial fluid.133 DNA of
varicella zoster virus, herpes simplex virus and adenoviruses is
only rarely detected in pericarditis patients. Cytomegalovirus
(CMV)-associated pericarditis is mainly found in immunocomprom-
ised and HIV patients.1 In developing countries with a delayed roll-
out of antiretroviral therapy, HIV-associated inflammatory reactions
(often related to TB) of the pericardium and myocardium are com-
mon complications.139 However, at present these investigations are
usually not performed because of their complexity, cost, invasive na-
ture and low availability.
5.1.6 Therapy
Acute viral pericarditis often presents as a self-limiting disease
that responds well to a short course of treatment with NSAIDs,
with the adjunct of colchicine, especially for prevention of
recurrences.4– 6,50,58,59 The identification of specific viral signatures
aids in understanding the pathogenetic mechanisms in pericarditis,
and might enable an individualized aetiologically driven specific
treatment approach to be established by distinguishing a viral aeti-
ology from autoreactive inflammation.133 Some experts suggest
antiviral treatment similar to that for myocarditis (IVIG therapy in
acute systemic enteroviral, CMV, EBV and parvovirus B19 infection,
oral valganciclovir in HHV-6 perimyocarditis, IFN-a for enteroviral
pericarditis).133 However, these treatments are still under evalu-
ation and rarely used. Involvement of infectious disease specialists
is recommended. So far, no therapy is available to solve the problem
of virus persistence and consecutive inflammation, particularly when
induced by herpesviruses and parvovirus B19 infections.133 Import-
antly, corticosteroids are generally not indicated in viral pericarditis,
as they are known to reactivate many virus infections and thus lead
to ongoing inflammation.133
Recommendations for the diagnosis and therapy of
viral pericarditis
Recommendations Classa Levelb Ref.c
For the definited diagnosis of viral
pericarditis, a comprehensive workup of
histological, cytological,
immunohistological and molecular
investigations in pericardial fluid and
peri-/epicardial biopsies should be
considered
IIa C
Routine viral serology is not
recommended, with the possible
exception of HIV and HCV
III C
Corticosteroid therapy is not
recommended in viral pericarditis
III C
HCV ¼ hepatitis C virus; HIV ¼ human immunodeficiency virus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dIn the absence of such an argument, the term ‘presumed viral pericarditis’
should be used.
5.2 Bacterial pericarditis
Bacterial pericarditis is relatively uncommon in clinical practice in
developed countries with a low prevalence of TB. Tuberculous peri-
carditis is the most common form all over the world and the most
common cause of pericardial diseases in developing countries. We
will discuss this form and also purulent pericarditis, which is less
common.
5.2.1 Tuberculous pericarditis
Tuberculous pericarditis accounts for ≤4% of pericardial disease in
the developed world.5,6,52. In contrast, TB is the cause of clinically
significant pericardial effusion in .90% of HIV-infected and 50–
70% of non-HIV-infected individuals who live in developing coun-
tries where TB is endemic.77 The disease can occur at any age,
and men are affected more frequently than women.140 Clinical evi-
dence of chronic cardiac compression mimicking congestive heart
failure is the most common presentation.79,93 Clinical presentations
are pericardial effusion, effusive-constrictive pericarditis and con-
strictive pericarditis.79 Tuberculous pericarditis has a mortality
rate of 17–40% at 6 months after diagnosis.141 It should be empha-
sized that the majority of the information on tuberculous
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pericarditis comes from endemic areas in underdeveloped coun-
tries and immunodepressed patients. The applicability of this infor-
mation to the Western world is questionable.
5.2.1.1 Diagnosis
A ‘definite’ diagnosis of tuberculous pericarditis is based on the
presence of tubercle bacilli in the pericardial fluid or on histological
section of the pericardium, by culture or by PCR (Xpert MTB/RIF)
testing; a ‘probable’ diagnosis is made when there is proof of TB
elsewhere in a patient with unexplained pericarditis, a lymphocytic
pericardial exudate with elevated unstimulated interferon-gamma
(uIFN-g), adenosine deaminase (ADA) or lysozyme levels and/or
an appropriate response to antituberculosis chemotherapy in en-
demic areas.79 uIFN-g offers superior accuracy for the diagnosis
of microbiologically confirmed tuberculous pericarditis compared
with the ADA assay and the Xpert MTB/RIF test.142 A protocol
for the evaluation of suspected tuberculous pericardial effusion is
proposed in Table 17.
5.2.1.2 Management
A regimen consisting of rifampicin, isoniazid, pyrazinamide and eth-
ambutol for at least 2 months followed by isoniazid and rifampicin
(total of 6 months of therapy) is effective in treating extrapulmonary
TB. Treatment for ≥9 months gives no better results and has the
disadvantages of increased cost and increased risk of poor
compliance.143
The evolution towards constrictive pericarditis is a serious poten-
tial complication. Constriction generally develops within 6 months
of presentation with effusive pericarditis (effusive-constrictive peri-
carditis).79 Tuberculous pericardial constriction is almost always as-
sociated with pericardial thickening. Prior to the introduction of
effective TB chemotherapy, up to 50% of patients with effusive tu-
berculous pericarditis progressed to constriction. Rifampicin-based
antituberculosis treatment reduced the incidence of constriction to
17–40%. Appropriate antibiotic therapy is essential to prevent this
progression.79,144 In addition, two interventions may reduce the in-
cidence of constriction: the first is intrapericardial urokinase145 and
second, the Investigation of the Management of Pericarditis (IMPI)
trial has shown that high-dose adjunctive prednisolone reduces
the incidence of constrictive pericarditis by 46% regardless of HIV
status.97
Adjunctive corticosteroid therapy with prednisolone for 6 weeks
had a neutral effect on the combined outcome of death from all
causes, cardiac tamponade requiring pericardiocentesis or peri-
cardial constriction; however, this therapy was associated with an
increased risk of HIV-associated malignancies in the prednisolone-
Table 17 A step-wise protocol for the evaluation of suspected tuberculous pericarditis and pericardial effusion
Stage 1: Initial 
non-invasive 
evaluation
• Chest radiograph may reveal changes suggestive of pulmonary tuberculosis in 30% of cases. 
• Echocar  
 or a tuberculous aetiology.
• CT scan and/or MRI of the chest are alternative imaging modalities where available:  look for evidence of pericardial effusion and  
 thickening (>3 mm), and typical mediastinal and tracheobronchial lymphadenopathy (>10 mm, hypodense centres, matting), with  
 sparing of hilar lymph nodes. 
• Culture of sputum, gastric aspirate, and/or urine for Mycobacterium tuberculosis (M. tuberculosis) should be considered in all  
 patients.
• Scalene l
• Tuberculin skin test is not helpful in adults regardless of the background prevalence of tuberculosis.
• If pericar ≥6 based on the following criteria is highly suggestive of tuberculous  
 pericarditis in people living in endemic areas: fever (1), night sweats (1), weight loss (2), globulin level >40 g/L (3) and peripheral  
 leucocyte count <10x109 /L (3).
Stage 2: 
Pericardiocentesis
• Therapeutic pericardiocentesis is absolutely indicated in the presence of cardiac tamponade.
• Diagnostic pericardiocentesis should be considered in all patients with suspected tuberculous pericarditis, and the following tests  
 perf
1. Dir
 culture for M. tuberculosis.
2. Quantitative polymerase chain reaction (Xpert MTB/RIF) testing for nucleic acids of M. tuberculosis.
3. Biochemical tests to distinguish betw
4. White cell analysis and count, and cytology: a lymphocytic exudate favours tuberculous pericarditis.
5. Indirect tests for tuberculous infection: interferon-gamma (IFN-y), adenosine deaminase (ADA), or lysozyme assay.
Stage 3: Pericardial 
biopsy
• “Therapeutic” biopsy: as part of surgical drainage in patients with cardiac tamponade relapsing after pericardiocentesis or requiring 
 open drainage of pericar
 medical therapy.
• Diagnostic biopsy: In areas where tuberculosis is endemic, a diagnostic biopsy is not required prior to commencing empiric 
 antituberculosis treatment. In areas where tuberculosis is not endemic, a diagnostic biopsy is recommended in patients with 
 >3 weeks of illness and without aetiologic diagnosis having been reached by other tests.
Stage 4: Empiric 
antituberculosis 
chemotherapy
• Tuberculosis endemic in the population: trial of empiric antituberculosis chemotherapy is recommended for exudative pericardial  
 effusion, after excluding other causes such as malignancy, uraemia, trauma, purulent pericarditis, and auto-immune diseases.
• Tuberculosis not endemic in the population: when systematic investigation fails to yield a diagnosis of tuberculous pericarditis, there 
 or starting antituberculosis treatment empirically.
ADA ¼ adenosine deaminase; CT ¼ computed tomography; LDH ¼ lactate dehydrogenase; MRI ¼ magnetic resonance imaging; TB ¼ tuberculosis.
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treated group.97 Adjunctive steroid therapy was associated with a
reduced incidence of pericardial constriction and hospitalization.
The beneficial effects of prednisolone on constriction and hospital-
ization were similar in HIV-positive and HIV-negative patients. On
this basis, it may be reasonable to use adjunctive corticosteroids
in patients with tuberculous pericarditis without HIV infection and
to avoid them in HIV-infected individuals because of the increased
risk of malignancy.97
Recommendations for the diagnosis and treatment of
tuberculous pericarditis and effusion
Recommendations Classa Levelb Ref.c
Diagnostic pericardiocentesis should be
considered in all patients with suspected
tuberculous pericarditis
IIa C
Intrapericardial urokinase may be
considered to reduce the risk of
constriction in tuberculous effusive
pericarditis
IIb C
In patients living in non-endemic areas,
empiric antituberculosis treatment is
not recommended when systematic
investigation fails to yield a diagnosis
of tuberculous pericarditis
III C
In patients living in endemic areas,
empiric antituberculosis chemotherapy
is recommended for exudative
pericardial effusion, after excluding
other causes
I C
Adjunctive steroids may be considered
in HIV-negative cases of TB pericarditis
and avoided in HIV-associated TB
pericarditis
IIb C
HIV ¼ human immunodeficiency virus; TB ¼ tuberculosis.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
Recommendations for the general management of
constrictive tuberculous pericarditis
Recommendations Classa Levelb Ref.c
Standard antituberculosis drugs for
6 months is recommended for the
prevention of tuberculous pericardial
constriction
I C
Pericardiectomy is recommended if the
patient’s condition is not improving or is
deteriorating after 4–8 weeks of
antituberculosis therapy
I C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.2.2 Purulent pericarditis
5.2.2.1 Epidemiology
Purulent pericarditis is rare, accounting for ,1% of cases.5,6 In West-
ern series, the most common organisms have been staphylococci,
streptococci and pneumococci, while the predominant associated le-
sions were empyema (50%) or pneumonia (33%).146 In immunosup-
pressed patients or following thoracic surgery, Staphylococcus aureus
(30%) and fungi (20%) are more common.147 Also, anaerobes origin-
ating from the oropharynx have been reported.148 Seeding may be
haematogenous or by contiguous spread from the retropharyngeal
space, cardiac valves and below the diaphragm.149 Neisseria meningiti-
dis may involve the pericardium either through initiating an immune-
mediated sterile effusion or by direct infection and purulent reaction.
The modern era of iatrogenic and HIV-associated immunosuppres-
sion has witnessed more unusual organisms.
5.2.2.2 Diagnosis
Purulent pericarditis is rare and generally manifested as a serious
febrile disease. The underlying sepsis may predominate the
illness.146 – 149 Suspicion of purulent pericarditis is an indication for
urgent pericardiocentesis,1,5,12 which is diagnostic. The fluid may
be frankly purulent. A low pericardial:serum glucose ratio (mean
0.3) and elevated pericardial fluid white cell count with a high pro-
portion of neutrophils (mean cell count 2.8/ml, 92% neutrophils)
differentiate purulent from tuberculous (glucose ratio 0.7, count
1.7/ml, 50% neutrophils) and neoplastic (glucose ratio 0.8, count
3.3/ml, 55% neutrophils) pericarditis.150 Fluid should be sent for bac-
terial, fungal and tuberculous studies, with blood for cultures and
other samples being taken as guided by the clinical presentation.12
5.2.2.3 Management
Purulent pericarditis should be managed aggressively, as death is inev-
itable if untreated, whereas with comprehensive therapy 85% of cases
have been reported to survive the episode and have a good long-term
outcome.50,146 Intravenous antimicrobial therapy should be started
empirically until microbiological results are available. Drainage is crucial.
Purulent effusions are often heavily loculated and likely to rapidly re-
accumulate. Intrapericardial thrombolysis is a possible treatment for
cases with loculated effusions in order to achieve adequate drainage be-
fore resorting to surgery.151 Subxiphoid pericardiostomy and rinsing of
the pericardial cavity should be considered.1 This allows more com-
plete drainage of the effusion, as loculations can be manually lysed.
Recommendations for the diagnosis of purulent
pericarditis
Recommendations Classa Levelb Ref.c
Urgent pericardiocentesis is
recommended for the diagnosis of
purulent pericarditis
I C
It is recommended that pericardial fluid
be sent for bacterial, fungal and
tuberculous studies and blood drawn for
cultures
I C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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Recommendations for the therapy of purulent
pericarditis
Recommendations Classa Levelb Ref.c
Effective pericardial drainage is
recommended for purulent pericarditis
I C
Administration of intravenous
antibiotics is indicated to treat purulent
pericarditis
I C
Subxiphoid pericardiotomy and rinsing
of the pericardial cavity should be
considered
IIa C
Intrapericardial thrombolysis should be
considered
IIa C
Pericardiectomy for dense adhesions,
loculated or thick purulent effusion,
recurrence of tamponade, persistent
infection and progression to constriction
should be considered
IIa C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.3 Pericarditis in renal failure
Renal disease and overall ESRD are associated with possible
pericardial involvement.152 Three different pathologies are found
in uraemic patients: uraemic pericarditis—before renal replace-
ment therapy or within 8 weeks of its initiation; dialysis pericardi-
tis—after being stabilized on dialysis (usually ≥8 weeks after its
initiation)153 and, very rarely, constrictive pericarditis. The global
incidence of pericarditis in ESDR patients has declined to 5%
in those patients starting dialysis.152 The reported frequency of
dialysis pericarditis ranges from 2 to 21%, but recent data are
lacking.
Pericardial involvement in ESRD is manifested most commonly as
acute pericarditis and chronic pericardial effusion and infrequently
as chronic constrictive pericarditis. Typical features of this form of
pericarditis include a lower rate of pleuritic chest pain (up to 30%
of patients are asymptomatic) and the absence of ECG abnormal-
ities in most cases, probably due to the lack of myocardial inflamma-
tion.152 – 154 Patients with ESRD are more likely to develop chronic
pericardial effusion due to continuous volume overload.152 Not all
pericardial effusions result from inflammation, and the normal vol-
ume of pericardial fluid is larger in stable haemodialysis patients
than in normal controls.155 With the advent of advanced renal re-
placement therapy, the incidence of haemodynamically significant
effusions has decreased.152,156,157 The most probable cause of ur-
aemic pericarditis is the retention of toxic metabolites.152,157 Since
pericardial effusion is often bloody in uraemic patients, anticoagula-
tion should be carefully considered or avoided in patients starting
dialysis.152,157
Recommendations for the management of pericarditis
in renal failure
Recommendations Classa Levelb Ref.c
Dialysis should be considered in uraemic
pericarditis
IIa C
When patients with adequate dialysis
develop pericarditis, intensifying dialysis
should be considered
IIa C
Pericardial aspiration and/or drainage
may be considered in non-responsive
patients with dialysis
IIb C
NSAIDs and corticosteroids
(systemic or intrapericardial) may be
considered when intensive dialysis is
ineffective
IIb C
Colchicine is contraindicated in
patients with pericarditis and severe
renal impairment (see Web Table 1B)
III C
NSAIDs ¼ non-steroidal anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.4 Pericardial involvement in systemic
autoimmune and autoinflammatory
diseases
Pericardial involvement in systemic autoimmune diseases may be
symptomatic (pericarditis and symptomatic pericardial effusion)
or asymptomatic (usually pericardial effusion) and generally re-
flects the degree of activity of the underlying disease.45 Approxi-
mately 5–15% of patients with acute or recurrent pericarditis
may have a systemic autoimmune disease, either overt or under-
lying (Table 1, Web Table 5).9,77,129 – 131 Pericardial involvement is
common in systemic lupus erythematosus, Sjo¨gren’s syndrome,
rheumatoid arthritis and scleroderma, but may also be present in
systemic vasculitides, Behc¸et’s syndrome, sarcoidosis and inflam-
matory bowel diseases. Pericardial involvement rarely occurs as
the first manifestation of these diseases. In most patients the
underlying disease has already been diagnosed by classical symp-
toms and signs. Concomitant myocardial inflammatory involve-
ment may complicate the presentation and should be ruled out.
If clinical features suggest a possible systemic autoimmune disease,
a targeted aetiological search is warranted in cooperation with
specialist consultation. The treatment is especially targeted at con-
trol of the systemic underlying disease.45
A specific subset of patients includes those with periodic fevers.
These are genetic disorders characterized by mutations of genes in-
volved in the regulation of the inflammatory response, without in-
volvement of specific T cells or autoantibodies.158 – 161 These
disorders are usually detected in the paediatric population, although
some patients experience disease onset during adulthood. The most
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common autoinflammatory syndromes include familial Mediterra-
nean fever (FMF), in which serositis episodes last only 1–3 days,
and tumour necrosis factor receptor-associated periodic syndrome
(TRAPS), in which the episodes last for weeks. Mutations associated
with these disorders are rare in recurrent pericarditis.158 –161 These
conditions may be characterized by an exaggerated expression of
IL-1.161 A 10% rate of familial occurrence of pericarditis has been re-
ported among the relatives of these patients.162 –164 These data sug-
gest a genetic predisposition in at least a subset of patients;
counselling may be warranted in these cases. A positive family his-
tory for pericarditis or periodic fevers, a poor response to colchi-
cine, as well as the need for immunosuppressive agents are clues
to the possible presence of an auto-inflammatory disease;160 par-
ticularly in these conditions, anti-IL-1 or anti-TNF agents may be
considered.31,32,160
5.5 Post-cardiac injury syndromes
The term post-cardiac injury syndromes (PCIS) is an umbrella term
indicating a group of inflammatory pericardial syndromes including
post-myocardial infarction pericarditis, post-pericardiotomy syn-
drome (PPS) and post-traumatic pericarditis (either iatrogenic or
not).132 Such syndromes are presumed to have an autoimmune
pathogenesis triggered by initial damage to pericardial and/or pleural
tissues caused by either myocardial necrosis (late post-myocardial
infarction pericarditis or Dressler syndrome), surgical trauma
(PPS), accidental thoracic trauma (traumatic pericarditis) or iatro-
genic trauma with or without bleeding (pericarditis after invasive
cardiac interventions).131 The immune-mediated pathogenesis is
supported by a latent period generally of a few weeks until the ap-
pearance of the first manifestations and the response to anti-
inflammatory drugs (NSAIDs, corticosteroids, colchicine) with the
possibility of recurrences. Pericardial bleeding and pleura incision
are triggers for the syndrome.165,166 Some forms, such as Dressler
syndrome, have become rare with early reperfusion therapy of myo-
cardial infarction; however, it may occur especially in cases of even
minor bleeding into the pericardium.167
5.5.1 Definition and diagnosis
According to proposed diagnostic criteria for PPS,168 – 170 the diag-
nosis of PCIS may be reached after a cardiac injury following clinical
criteria: (i) fever without alternative causes, (ii) pericarditic or pleur-
itic chest pain, (iii) pericardial or pleural rubs, (iv) evidence of peri-
cardial effusion and/or (v) pleural effusion with elevated CRP. At
least two of five criteria should be fulfilled. The rationale for propos-
ing specific criteria instead of adopting the same for pericarditis is
that these syndromes may have concomitant pleuropericardial in-
volvement and possible pulmonary infiltrates, and are not simply
pericarditis.170 Moreover, it is sometimes difficult to differentiate
PCIS from the simple mechanical consequences of surgery (such
as pericardial or pleural effusion). The demonstration of inflamma-
tory activity should be essential to establish the diagnosis. Basic diag-
nostic evaluation of a patient with a suspected PCIS includes physical
examination, ECG, echocardiogram, thoracic echography and/or
chest X-ray.132,165 On this basis, echocardiography is recommended
when an iatrogenic complication is suspected after a cardiovascular
intervention.2,3,132
5.5.2 Management
Treatment of PCIS is essentially based on empiric anti-inflammatory
therapy, and may improve remission rates and reduce the risk of
recurrences.171 The same therapeutic scheme adopted for peri-
carditis is efficacious for all these forms, including post-myocardial
infarction pericarditis (Table 3). Colchicine is not recommended
for postoperative effusions in the absence of systemic inflamma-
tion.172– 174 Similarly NSAIDs are generally not indicated in asymp-
tomatic post-surgical effusions, and this therapy may be associated
with an increased risk of side effects related to NSAIDs.173,174
5.5.3 Prevention
Different preventive strategies have been examined in a few studies
regarding aspirin,175 methylprednisone,176 dexamethasone177 and
colchicine.168,169,172 Four controlled clinical trials for primary pre-
vention of PPS were included in a systematic review on 894 patients;
three studies were double-blind RCTs. Treatment comparisons
were colchicine vs. placebo (two RCTs enrolling 471 patients),
methylprednisolone vs. placebo (one RCT involving 246 paediatric
patients) and aspirin vs. historical controls (one non-randomized
study involving 177 paediatric patients). Meta-analytic pooling
showed that only colchicine was associated with decreased risk of
PPS [odds ratio (OR) 0.38]. Data on methylprednisolone (OR
1.13) and aspirin (OR 1.00) were negative.178 The Colchicine for
Prevention of the Post-pericardiotomy Syndrome and Post-
operative Atrial Fibrillation (COPPS-2) trial confirmed the overall
efficacy of perioperative use of colchicine, but it was also found to
be associated with an increased risk of gastrointestinal side effects172
compared with postoperative use of colchicine.169 Colchicine is not
recommended for the perioperative treatment and prevention of
postoperative effusions in the absence of systemic inflammation.172
In another trial,177 high-dose dexamethasone (1 mg/kg as a single in-
traoperative dose) was not efficacious in preventing PPS or compli-
cated PPS.
5.5.4 Prognosis
Despite limited published data, the prognosis of PPS is generally
good.178 There are very few available data on other forms of post-
pericardial injury syndromes. In the largest published series on PPS
patients after cardiac surgery,166 complication rates were low: ,4%
for recurrences, ,2% for cardiac tamponade and no cases of con-
striction, although hospital stay may be prolonged in these patients.
However, the development of constrictive pericarditis has been re-
ported in 3% of cases.36
5.5.4.1 Post-myocardial infarction pericarditis
Following an acute myocardial infarction (AMI), three major pericar-
dial complications may occur: (i) pericardial effusion, (ii) early
infarct-associated pericarditis (often called early post-infarction
pericarditis, typically a few days after AMI) and (iii) late pericarditis
or post-cardiac injury (Dressler) syndrome (typically 1–2 weeks
after AMI).
Early post-infarction pericarditis usually occurs soon after the
AMI and is transient. This complication is rare in the primary percu-
taneous coronary intervention era and is especially related to late
reperfusion or failed coronary reperfusion.167 Diagnostic criteria
do not differ from those for acute pericarditis. ECG changes are
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usually overshadowed by changes due to the myocardial infarction.
However, ST segments may remain elevated, with persistence of up-
right T waves, as T waves may become upright again after having
been inverted. Echocardiography should be performed in patients
suspected of having post-AMI to evaluate for the presence of a peri-
cardial effusion. CMR can be used to show the presence of con-
comitant pericardial inflammation.179 Patients with a post-AMI
pericardial effusion .10 mm in thickness should be investigated
for a possible subacute rupture.180,181 The treatment is generally
supportive, as most cases are self-limited. However, a minority of
patients may have persistent symptoms that require more than sup-
portive care. For these patients, aspirin plus colchicine may be
considered.
Late post-AMI pericarditis (Dressler syndrome) is rare (,1%)
in the era of primary percutaneous coronary intervention and
may reflect a larger size of AMI and/or late reperfusion.167 Diagno-
sis and treatment are similar to that generally recommended
for PCIS.
Although pericarditis is associated with a larger infarct size, in-
hospital and 1-year mortality and major adverse cardiac events
were similar in patients with and without pericarditis. Timely pri-
mary percutaneous coronary intervention may reduce the occur-
rence of post-AMI pericarditis. Early post-AMI pericarditis remains
a marker of larger infarct size, but without independent prognostic
significance.167
5.5.4.2 Postoperative effusions
Postoperative pericardial effusions are relatively common after car-
diac surgery. They usually disappear in 7–10 days, but sometimes
they persist for longer and can be dangerous. Early post-cardiac sur-
gery pericardial collections must be interpreted in the clinical con-
text of the patient. They have been reported as asymptomatic in
22% of patients 2 weeks after cardiac surgery.182 The prognosis is
good for mild effusions occurring in two of three cases, but moder-
ate to large effusions (one of three) may progress to cardiac tam-
ponade in 10% of cases 1 month after cardiac surgery.182,183
Treatment of these asymptomatic effusions by diclofenac was
shown to be useless in the Post-Operative Pericardial Effusion
(POPE) trial and may be associated with an increased risk of side ef-
fects related to NSAID use.173 In contrast, cardiac tamponade oc-
curring in the first hours after cardiac surgery is usually due to
haemorrhage in the pericardial space, and surgical reintervention
is mandatory in this situation.
Recommendations for the management and
prevention of post-cardiac injury syndromes
Recommendations Classa Levelb Ref.c
Anti-inflammatory therapy is
recommended in patients with PCIS to
hasten symptom remission and reduce
recurrences
I B 171
Aspirind is recommended as a first
choice for anti-inflammatory therapy of
post-myocardial infarction pericarditis
and those patients already on
antiplatelet therapies
I C
Colchicine added to aspirin or
NSAIDs should be considered for
the therapy of PCIS, as in acute
pericarditis
IIa B 58
Colchicine should be considered
after cardiac surgery using
weight-adjusted doses (i.e. 0.5 mg
once for patients ≤70 kg and 0.5 mg
twice daily for patients .70 kg) and
without a loading dose for the
prevention of PPS if there are no
contraindications and it is tolerated.
Preventive administration of colchicine is
recommended for 1 month
IIa A
168,
169
Careful follow-up after PCIS
should be considered to exclude
possible evolution towards
constrictive pericarditis with
echocardiography every 6–12 months
according to clinical features and
symptoms
IIa C
NSAIDs ¼ non-steroidal anti-inflammatory drugs; PCIS ¼ post-cardiac injury
syndromes; PPS ¼ post-pericardiotomy syndrome.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dAntiplatelet effects of aspirin have been demonstrated for doses up to 1.5 g/day.
There are no data for or against the use of higher doses in this setting.
5.6 Traumatic pericardial effusion and
haemopericardium
Any cardiac intervention (e.g. percutaneous coronary intervention,
pacemaker lead insertion, radiofrequency ablation) may be respon-
sible for haemopericardium and cardiac tamponade due to coron-
ary or cardiac chamber perforation. Pericardial effusion induced
by trauma is included in the more expanded concept of PCIS.132
However, in the event of overt chest trauma complicated by cardiac
tamponade, the magnitude of the trauma is the main cause of the
syndrome. Diagnosis includes the presence of a prior history of
chest trauma as a trigger for the syndrome plus the signs and symp-
toms of pericarditis (i.e. chest pain, pericardial rub, dyspnoea, low-
grade fever) and markers of inflammatory reaction (i.e. elevated
CRP, leucocytosis, ESR). ECG is normally used to rule out AMI as
a possible cause of pericarditis. Chest X-ray may help to detect car-
diomegaly and pleural effusions. Transthoracic echocardiography is
used to detect the presence, size and haemodynamic importance of
the pericardial effusion. A recent randomized trial demonstrated
that the use of limited transthoracic echocardiography improved
the time from the trauma bay to the operating room and reduced
the mortality rate.184
Therefore treatment differs according to the severity of the syn-
drome. For those with post-traumatic pericarditis with no haemo-
dynamic compromise, treatment is essentially based on empirical
anti-inflammatory therapy and adjunctive colchicine, which has
been shown to be safe and efficacious for the prevention of pericar-
ditis.57 For those life-threatening cases of penetrating trauma to the
heart and chest, emergency thoracotomy is recommended to im-
prove survival as opposed to the classic strategy of initial
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pericardiocentesis as a bridge to surgery.185,186 This is usually done
through left anterolateral thoracotomy that makes pericardiotomy
possible with effective relief of cardiac tamponade and direct cardiac
massage if needed.
In the setting of aortic dissection with haemopericardium and sus-
picion of cardiac tamponade, emergency transthoracic echo-
cardiography or a CT scan should be performed to confirm the
diagnosis. In such a scenario, controlled pericardial drainage of
very small amounts of the haemopericardium can be attempted to
temporarily stabilize the patient in order to maintain blood pressure
at 90 mmHg.187
Recommendations for the management of traumatic
pericardial effusion and haemopericardium in aortic
dissection
Recommendations Classa Levelb Ref.c
Urgent imaging technique (transthoracic
echocardiogram or CT) is indicated
in patients with a history of chest trauma
and systemic arterial hypotension
I B 184
Immediate thoracotomy is indicated in
cardiac tamponade due to penetrating
trauma to the heart and chest
I B 185
In the setting of aortic dissection
with haemopericardium, controlled
pericardial drainage of very small
amounts of the haemopericardium
should be considered to temporarily
stabilize the patient in order to
maintain blood pressure at about
90 mmHg
IIa C
Pericardiocentesis as a bridge to
thoracotomy may be considered in
cardiac tamponade due to penetrating
trauma to the heart and chest
IIb B 185
CT ¼ computed tomography.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.7 Pericardial involvement in neoplastic
disease
The differential diagnosis between malignant processes and other
causes of pericarditis is particularly relevant and generally is ac-
complished by imaging, e.g. CT scan, cytology of pericardial fluid
and eventually biopsies. Primary tumours of the pericardium, ei-
ther benign (lipomas and fibromas) or malignant (mesotheliomas,
angiosarcomas, fibrosarcomas), are very rare.188,189 Mesotheli-
oma, the most common malignant tumour, is almost always incur-
able. The most common secondary malignant tumours are lung
cancer, breast cancer, malignant melanoma, lymphomas and leu-
kaemias. Malignant pericardial effusions may be small, medium
or large, with an imminent tamponade (frequent recurrences)
or constriction; they may even be the initial sign of malignant
disease.190 The diagnosis is based on confirmation of the malig-
nant infiltration within the pericardium.188,189 Of note, in almost
two-thirds of patients with documented malignancy, pericardial
effusion is caused by non-malignant diseases, e.g. radiation peri-
carditis, other therapies or opportunistic infections.189 Chest
X-ray, CT, PET and CMR may reveal mediastinal widening, hilar
masses and pleural effusion. Analyses of pericardial fluid and peri-
cardial or epicardial biopsies are essential for the confirmation of
malignant pericardial disease.188 – 191
The diagnostic yield of the concentrations of tumour markers in
pericardial fluid remains controversial: carcinoembryonic antigen
(CEA), CYFRA 21–1, neuron-specific enolase (NSE), CA-19–9,
CA- 72–4, SCC, GATA3 and VEGF may be useful, but none of these
tumour markers has been proven to be accurate enough for distin-
guishing malignant from benign effusions.192,193 Epidermal growth
factor receptor (EGFR) mutation should be evaluated and has
prognostic indications in patients with malignant pericardial effusion
in the course of lung adenocarcinoma194 in order to tailor the
treatment.
Treatment of cardiac tamponade is a class I indication for peri-
cardiocentesis. The following steps are recommended in large
suspected neoplastic pericardial effusion without tamponade:
(i) systemic antineoplastic treatment as baseline therapy,189 (ii)
pericardiocentesis to relieve symptoms and establish a diagnosis
and (iii) intrapericardial instillation of cytostatic/sclerosing agents
to prevent recurrences. Pericardial drainage is recommended in
all patients with large effusions because of the high recurrence
rate (40–70%).193 – 196 Prevention of recurrences may be achieved
by intrapericardial instillation of sclerosing and cytotoxic
agents.197 – 204 Intrapericardial treatment should be tailored to
the type of tumour: cisplatin was most effective in pericardial in-
volvement in the course of lung cancer200,204 and thiotepa was
more effective in breast cancer pericardial metastases.197,198 Tet-
racyclines as sclerosing agents also control malignant pericardial
effusion in 85% of cases, but side effects and complications are
quite frequent: fever (19%), chest pain (20%) and atrial arrhythmias
(10%).189,199 Radiation therapy is very effective (93%) in control-
ling malignant pericardial effusion in patients with radiosensitive
tumours such as lymphomas and leukaemias. However, radiother-
apy of the heart can cause myocarditis and pericarditis.189 Pericar-
diotomy is indicated when pericardiocentesis cannot be
performed.205 The procedure can be carried out under local an-
aesthesia, but complications include myocardial laceration,
pneumothorax and mortality.189,205 Surgical pericardiotomy
does not improve clinical outcomes over pericardiocentesis
and is associated with a higher rate of complications.202 Pleuro-
pericardiotomy allows drainage of malignant pericardial fluid
into the pleural space. It is associated with a higher complication
rate and offers no advantage over pericardiocentesis or pericar-
diotomy. Pericardiectomy is rarely indicated, mainly for pericardial
constriction or complications of previous procedures.189 Percu-
taneous balloon pericardiotomy creates a pleuropericardial direct
communication, which allows fluid drainage into the pleural
space: in large malignant pericardial effusions and recurrent
tamponade it seems to be effective (90–97%) and safe.204 Pericar-
dial window creation via left minithoracotomy is a safe and effect-
ive approach in the surgical treatment of malignant cardiac
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tamponade.205 In clinical practice, management is often palliative at
late stages with advanced disease; it is aimed only at the relief of
symptoms rather than treatment of the underlying disease, taking
into account prognosis and the overall quality of life of the
patients.206
Recommendations for the diagnosis and management
of neoplastic involvement of the pericardium
Recommendations Classa Levelb Ref.c
Pericardiocentesis is recommended for
cardiac tamponade to relieve symptoms
and establish the diagnosis of malignant
pericardial effusion
I B
Cytological analyses of pericardial fluid are
recommended for the confirmation of
malignant pericardial disease
I B 191
Pericardial or epicardial biopsy should
be considered for the confirmation of
malignant pericardial disease
IIa B
Tumour marker testing should be
considered for distinguishing
malignant from benign effusions in
pericardial fluid
IIa B 193
Systemic antineoplastic treatment is
recommended in confirmed cases of
neoplastic aetiology
I B
Extended pericardial drainage is
recommended in patients with
suspected or definite neoplastic
pericardial effusion in order to prevent
effusion recurrence and provide
intrapericardial therapy
I B
Intrapericardial instillation of cytostatic/
sclerosing agents should be considered
since it may prevent recurrences in
patients with malignant pericardial
effusion
IIa B
197–
204
Intrapericardial cisplatin should be
considered in pericardial involvement in
the course of lung cancer and
intrapericardial instillation of thiotepa
should be considered in breast cancer
pericardial metastases
IIa B
197,
198,
200,
204
Radiation therapy should be
considered to control malignant
pericardial effusion in patients with
radiosensitive tumours such as
lymphomas and leukaemias
IIa B
Pericardiotomy should be considered
when pericardiocentesis cannot be
performed
IIa B 205
Percutaneous balloon pericardiotomy
may be considered for the prevention of
recurrences of neoplastic pericardial
effusions
IIb B
Pericardial window creation via left
minithoracotomy may be considered in
the surgical treatment of malignant
cardiac tamponade
IIb B 207
Interventional techniques should
consider seeding of neoplastic cells,
patient prognosis and the overall quality
of life of the patients
IIa C
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.8 Other forms of pericardial disease
5.8.1 Radiation pericarditis
Prior chest radiation is an important cause of pericardial disease. Most
cases are secondary to radiation therapy for Hodgkin’s lymphoma or
breast or lung cancer. Serious radiation-induced pericardial disease
was most often due to radiation therapy of Hodgkin’s lymphoma, al-
though the incidence of the condition has decreased with lower
doses and modern radiation therapy techniques (shielding and dose
calculation). As an example, the incidence of pericarditis decreased
from 20 to 2.5%.208 Less commonly, radiation exposure can cause
other conditions (e.g. oesophageal cancer) or can occur in association
with nuclear accidents. Soon after radiation the patient may develop
acute pericarditis with or without effusion.208 Late onset of pericar-
dial disease is common; it has been observed in up to 20% of patients
within 2 years following irradiation,209 with a latency of up to 15–20
years, and is not necessarily preceded by acute pericarditis.210 Late
pericardial disease may consist of effusive-constrictive pericarditis
or classical constrictive pericarditis (4–20% of patients) and appears
to be dose dependent and related to the presence of pericardial ef-
fusion in the delayed acute phase.209 Alternatively, radiation damage
may result in a large pericardial effusion, with or without tamponade.
The effusion may be serous or haemorrhagic and has a high probabil-
ity of developing fibrous adhesions. Therapies are similar to those em-
ployed in pericarditis and pericardial effusion. Therapeutic radiation
may cause other types of cardiac injury as well. The most serious is
radiation-induced cardiomyopathy, but the coronary arteries and
the cardiac valves may also be affected; this probably explains why
pericardiectomy for radiation-induced disease is associated with a
worse outcome than when performed for constrictive pericarditis re-
sulting from most other causes.
Recommendations for the prevention and
management of radiation pericarditis
Recommendations Classa Levelb Ref.c
Radiation therapy methods that reduce
both the volume and the dose of cardiac
irradiation are recommended whenever
possible
I C
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Pericardiectomy should be considered
for radiation-induced constrictive
pericarditis, but with a worse outcome
than when performed for constrictive
pericarditis of other causes, because of
co-existing myopathy
IIa B
91,92,
103,
106
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.8.2 Chylopericardium
Chylopericardium is a pericardial effusion composed of chyle,
the normal content of the lymphatic vessels. It is a rare disorder
that may be primary or, more often, secondary to injury to the
thoracic duct, which carries chyle from the intestinal tract to the
blood at the junction of the left internal jugular and left subclavian
veins.211 It is often associated with chylothorax. Cardiac complica-
tions are cardiac tamponade, acute pericarditis and chronic con-
striction. Causes are trauma, surgery (especially for congenital
heart disease), congenital lymphangiomatosis, radiotherapy, sub-
clavian vein thrombosis, infection (e.g. TB), mediastinal neoplasms
and acute pancreatitis.212 – 214 Primary chylopericardium is less
common and is a diagnosis by exclusion. CT with and without con-
trast enhancement or combined with lymphangiography/lymphan-
gioscintigraphy (rarely performed) can be used to identify injury
or blockage of the thoracic duct.
Chylopericardium should not be confused with cholesterol
pericarditis, in which the fluid is clear and occurs in tuberculous
pericarditis, rheumatoid pericarditis and trauma. The con-
centration of cholesterol equals or exceeds that of the blood.
Pericardiocentesis is seldom effective and optimal therapy
is radical pericardiectomy plus treatment of the underlying
cause.215,216
Recommendations for the diagnosis and management
of chylopericardium
Recommendations Classa Levelb Ref.c
Chylopericardium is diagnosed in the
presence of a milky opalescent
pericardial effusion, with a triglyceride
level .500 mg/dl,
cholesterol:triglyceride ratio ,1,
negative cultures and lymphocyte
predominance (lymphocyte count
between a few hundred to several
thousand per millilitre)
I C
Pericardial drainage and parenteral
nutrition should be considered in
symptomatic or large uncontrolled
effusion due to chylopericardium
IIa C
Surgical therapy should be considered
for chylopericardium if conservative
therapy does not reduce pericardial
drainage and the course of the thoracic
duct is identified
IIa C
Therapy with octreotide (100 mg
s.c. × 3/day for 2 weeks) may be
considered for chylopericardium (the
mechanism of action is presumed to be
a reduction in chyle production)
IIb C
s.c. ¼ subcutaneous.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
5.8.3 Drug-related pericarditis and pericardial effusion
Pericardial reactions to drugs are rare (Table 1). Pericardial damage
has also been associated with polymer fume inhalation, ‘serum sick-
ness’ by blood products or foreign antisera, venoms (scorpion fish
sting), foreign substance reactions by direct pericardial application
(e.g. talc, magnesium silicate), silicones, tetracyclines, sclerosants, as-
bestos and iron in b-thalassaemia.1 Management is based on discon-
tinuation of the causative agent and symptomatic treatment.
The use of heparin and anticoagulant therapies is often perceived
as a possible risk factor for the development of a worsening or
haemorrhagic pericardial effusion that may result in cardiac tampon-
ade, but a multivariable analysis of nearly 500 consecutive cases of
acute pericarditis did not show this to be the case.9 Similarly in an-
other study of 274 patients with acute pericarditis or myopericardi-
tis, the use of heparin or other anticoagulants was not associated
with an increased risk of cardiac tamponade.7 On the other hand,
in the setting of iatrogenic pericardial effusion, full anticoagulation
may be a risk factor for tamponade and complications.217
5.8.4 Pericardial effusion in metabolic and endocrine
disorders
The main cause of pericardial diseases in this setting is represented
by hypothyroidism. Pericardial effusion may occur in 5–30% of
patients with hypothyroidism, but recent data are lacking;218,219 it
may be quite large, but tamponade occurs rarely. It is diagnosed
by a high thyroid stimulating hormone (TSH) level, and clinically is
characterized by relative bradycardia and low QRS voltage in the
ECG.
5.8.5 Pericardial involvement in pulmonary arterial
hypertension
Pericardial effusion in the setting of pulmonary artery hypertension
(PAH) is common (25–30%) and typically small in size, but rarely
causes haemodynamic compromise. Pericardial effusion develop-
ment in PAH appears to relate to right ventricular failure and a sub-
sequent increase in right-sided filling pressures along with right atrial
hypertension and increased pressure in the thebesian veins and cor-
onary sinus. These processes result in increased filtration and
lymphatic obstruction, resulting in pericardial effusion.220
Diagnosis of cardiac tamponade in a patient with severe PAH is
challenging. Determining the haemodynamic significance of pericar-
dial effusions in PAH requires increased attention since high right-
sided pressures can mask many of the typical right-sided clinical
and echocardiographic findings of tamponade. Because there is ele-
vation in right-sided intracardiac chamber pressures, right-sided
chamber collapse is uncommon. In contrast, left atrial pressure is
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typically lower in PAH and therefore left atrial early diastolic col-
lapse is more commonly seen. Exaggerated ventricular interdepend-
ence, such as a decrease in left ventricular filling with early
inspiration, may also be present.
The presence of pericardial effusion has been associated with
connective tissue disease, shorter 6-minute walk distance and an
elevated B-type natriuretic peptide level. Even a small quantity of ex-
cess pericardial fluid in a patient with PAH portends a poor progno-
sis. Pericardial effusions in PAH appear to be a marker of
co-morbidity with either concomitant connective tissue disease
or high venous pressure; these two factors are recognized to confer
an adverse risk.220
5.8.6 Pericardial cysts
Pericardial cysts are rare mediastinal masses with an incidence of 1 in
100,000 patients131,221 that have been described as diverticulae or
cystic formations when an abnormal chest X-ray was obtained.
They represent 6% of mediastinal masses and 33% of mediastinal
cysts. Other cysts in the mediastinum are bronchogenic (34%), en-
teric (12%), thymic and others (21%).131,221 They are often found in
either one of the cardiophrenic angles.131,206,221 Cysts do not com-
municate with the pericardial space, whereas diverticulae do. They
may be uni- or multiloculated. Inflammatory cysts comprise pseudo-
cyst as well as encapsulated or loculated pericardial effusions caused
by rheumatic disorders, bacterial infection, trauma or cardiac sur-
gery. Echinococcal cysts usually originate from ruptured hydatid
cysts in the liver and the lungs. The differential diagnosis comprises
loculated pericardial effusions of unknown origin and malignant
pericardial masses. The diagnostic workup includes echocardiog-
raphy, CT and eventually CMR to define the size, density and neigh-
bouring structures.131,221 They are mostly asymptomatic and
detected incidentally, but can also present with chest discomfort,
dyspnoea or palpitations due to cardiac compression. The first
treatment for symptomatic congenital and inflammatory cysts is
percutaneous aspiration,206,222 possibly associated with ethanol
sclerosis.222 If the diagnosis is not completely established by imaging
or the cyst recurs after drainage, surgical resection may be neces-
sary. For echinococcal cysts, percutaneous aspiration and instillation
of ethanol or silver nitrate after pre-treatment with albendazole
(800 mg/day for 4 weeks) has been proposed.1
6. Age and gender issues in
pericardial diseases
6.1 Paediatric setting
Pericarditis accounts for 5% of all children who present with chest
pain to a paediatric emergency department.223 Children may be af-
fected by the same syndromes that affect adults.17 Diagnostic cri-
teria are the same and the risk of recurrence is similar (15–30%).
The aetiology is similar to that in adults, with PPS more often de-
scribed, particularly after interatrial defect correction.18 Compared
with adults, children often have a marked inflammatory clinical pat-
tern, with more commonly fever, pleuropulmonary involvement
and raised CRP and less commonly anti-nuclear antibody (ANA)
positivity. This might imply activation of inflammatory pathways
with release of IL-1.19
No RCT has been done in children. NSAIDs remain the main-
stay, at high dosages (Web Table 7). Most paediatricians avoid as-
pirin in children. Colchicine halved recurrences in children.19
Corticosteroid use should be restricted in children even more
than in adults, given that their side effects (striae rubre and
growth impairment) are particularly deleterious in growing
children; the minimal effective dose should be sought. Severe phys-
ical restriction is bothersome in children and may further worsen
their quality of life and that of their family. Anakinra (anti-IL-1
receptor) is a new option for children, especially if they are
corticosteroid-dependent.20 – 23
The long-term prognosis in children is good; however, quality of
life can be severely affected with repeated recurrences, glucocortic-
oid dependence and severe physical restriction.19
Recommendations for therapy of acute and recurrent
pericarditis in children
Recommendations Classa Levelb Ref.c
NSAIDs at high doses are recommended
as first-line therapy for acute pericarditis
in children until complete symptom
resolution (see Web Table 9 for dosages)
I C
Colchicine should be considered as an
adjunct to anti-inflammatory therapy for
acute recurrent pericarditis in children:
,5 years, 0.5 mg/day; .5 years, 1.0–1.5
mg/day in two to three divided doses
IIa C
Anti-IL-1 drugs may be considered in
children with recurrent pericarditis and
especially when they are corticosteroid
dependent
IIb C
Aspirin is not recommended in children
due to the associated risk of Reye’s
syndrome and hepatotoxicity
III C
Corticosteroids are not recommended
due to the severity of their side effects in
growing children, unless there are
specific indications such as autoimmune
diseases
III C
IL ¼ interleukin; NSAIDs ¼ non-steroidal anti-inflammatory drugs.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
6.2 Pregnancy, lactation and reproductive
issues
The most common form of pericardial involvement in pregnancy is
hydropericardium, usually as a benign mild effusion by the third tri-
mester, which is found in up to 40% of women, often occasionally.
The effusion is usually silent and clinical examination and ECG are
generally normal. In a few cases, slightly elevated blood pressure
and/or aspecific ST-T changes have been documented.24,25 The
most common disease to require medical therapy is acute pericar-
ditis; diagnosis is made using the usual criteria. No specific aetiology
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is usually identified. Nowadays the general outcomes of pregnancies
in these women when followed by dedicated multidisciplinary teams
are similar to those expected in the general population.25
A proposed treatment scheme for pericarditis during pregnancy
is described in Web Table 8.25 –27 Pregnancy in women with recur-
rent pericarditis should be planned during a phase of disease quies-
cence.25 – 27 Classic NSAIDs (ibuprofen, indomethacin) may be
considered during the first and second trimesters;25 – 27 most ex-
perts prefer high-dose aspirin, since it is regularly used in anti-
phospholipid syndrome in pregnancy and is moderately effective
in the prevention of pre-eclampsia in high-risk obstetric pa-
tients.224,225 After gestational week 20, all NSAIDs (except aspirin
≤100 mg/day) can cause constriction of the ductus arteriosus and
impair foetal renal function, and they should be withdrawn in any
case at gestational week 32.224,225 The lowest effective doses of
prednisone may be used throughout pregnancy and breastfeeding
(with supplementation with calcium and vitamin D).25– 27 Paraceta-
mol is allowed throughout pregnancy and breastfeeding, as are
anti-histamine H2 blockers or proton pump inhibitors.226 During
pregnancy, tapering of therapies should be extremely cautious. Nor-
mal vaginal delivery is possible and should be considered in the
absence of contraindications.25 – 27 Ibuprofen, indomethacin, na-
proxen and prednisone may be considered in women who are breast-
feeding. After discontinuation of breastfeeding, gradual tapering of
prednisone should be considered, eventually resuming colchicine.
Colchicine is considered contraindicated during pregnancy and
breastfeeding, even though no adverse events during pregnancy and
foetal or child development have been reported in women with FMF
treated with colchicine during pregnancy and breastfeeding.227–229
6.3 The elderly
Most guidelines have not discussed the applicability of their recom-
mendations to older patients with multiple co-morbidities.230 No
paper has specifically addressed pericardial diseases in the elderly,
so only expert opinion exists. Therapy adherence and compliance
may be problematic in the elderly because of cognitive impairment,
poor vision or hearing and cost, but the strongest predictor of non-
adherence is the number of medications.230 Indomethacin is not in-
dicated, the colchicine dose should be halved and particular care
should be taken to evaluate renal impairment and drug interactions.
7. Interventional techniques and
surgery
The aetiology of pericardial diseases remains unresolved in many
cases because the full spectrum of diagnostic methods is not used
in many institutions. The gold standard remains surgical by the sub-
xiphoid approach, allowing collection of fluid samples and perform-
ing pericardial biopsy and pericardial drainage. Interventional
techniques206 include the combined use of imaging by pericardio-
scopy first described in combination with diagnostic molecular,
histological and immunohistological methods to assess the aetiology
and pathogenesis of pericardial and epicardial disease manifesta-
tions133 and the option to intervene therapeutically by instillation
of drugs into the pericardial sac.63,204
7.1 Pericardiocentesis and pericardial
drainage
For pericardial drainage and biopsy, the surgical approach remains
the gold standard. The classical approach is by subxiphoid incision,
through which it is easy to take fluid samples and perform a pericar-
dial biopsy. The operation is completed by leaving a small drain in
place to evacuate remaining effusion. This technique using a subxi-
phoid approach is straightforward for a thoracic or cardiovascular
surgeon, if such a team is close to the cardiology team. In clinical
practice, pericardial fluid is aspirated by pericardiocentesis.
State-of-the-art pericardiocentesis must be guided either by
fluoroscopy or echocardiography206 under local anaesthesia. Blind
procedures must be not be used to avoid the risk of laceration of
the heart or other organs, except in very rare situations that are im-
mediately life threatening. An experienced operator and staff should
perform pericardiocentesis in a facility equipped for radiographic,
echocardiographic, haemodynamic and ECG monitoring.
For echo-guided pericardiocentesis, the ideal entry site is the
point on the body surface where the effusion is closest to the trans-
ducer and the fluid collection is maximal. The needle trajectory is
defined by the angulation of the handheld transducer and should
avoid vital structures such as the liver, myocardium, lung, internal
mammary artery (3–5 cm away from the parasternal border) and
the vascular bundle at the inferior margin of each rib. The intended
point of entry is marked on the skin and the direction of the ultra-
sound beam is carefully noted (see Web supplemental material). An
additional technique is the echo-guided approach followed by echo-
monitoring of the procedure.
For fluoroscopic-guided pericardiocentesis, a polytef-sheathed
needle with an attached saline-filled syringe is advanced under mod-
erate suction until the pericardial sac is reached.206 When using the
more common subxiphoid route for pericardiocentesis, a Tuohy-17,
blunt-tip introducer needle is advanced to the left shoulder at a
30-degree angle to the skin, thus avoiding coronary, pericardial and
internal mammary arteries. The lateral angiographic view provides
the best visualization of the puncturing needle and its relation to
the diaphragm and pericardium. The needle is slowly advanced to-
wards the heart shadow and the epicardial halo phenomenon, under
moderate suction and with injection of small amounts of diluted con-
trast medium, until pericardial fluid is aspirated. If haemorrhagic fluid
is freely aspirated, a few millilitres of contrast medium may be injected
under fluoroscopic control to verify the position of the needle. A soft
J-tip guidewire is then introduced and after dilatation is exchanged for
a multihole pigtail catheter, through which the fluid is evacuated un-
der the control of intrapericardial pressure.206
Pericardiocentesis should be performed by experienced opera-
tors and carries a risk of complications ranging from 4 to 10% de-
pending on the type of monitoring, the skill of the operator and
the setting (emergency vs. urgent vs. elective).183,206 Most common
complications include arrhythmias, coronary artery or cardiac
chamber puncture, haemothorax, pneumothorax, pneumopericar-
dium and hepatic injury (Web Table 9).
Pericardiocentesis may have additional limitations/dangers when
pericardial fluid is not free and when located in a lateral or posterior
position or ,10 mm. In these cases a surgical approach might be
safer, depending on local expertise and availability.
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7.2 Pericardioscopy
Pericardioscopy permits visualization of the pericardial sac with its
epicardial and pericardial layers. Macroscopic views show a cluster-
ing of protrusions, haemorrhagic areas and neovascularization in
malignant pericardial effusion, which are often haemorrhagic, in con-
trast to radiogenic or viral and autoimmune effusions.133,206
Pericardioscopy enables the performing physician to take targeted
biopsy specimens from epicardial and pericardial layers, avoiding epi-
cardial vessels and increasing the probability of obtaining disease-
specific results. For safety reasons it is important to have a second
wire in place. The safety wire allows a quick exchange with a pigtail
catheter and allows autotransfusion in the case of relevant bleeding.
By selecting the biopsy site, less informative white areas of fibrin can
be avoided and dark spots of inflammation, malignancy or haemor-
rhagic imbibitions can be selected, which can be identified best in
the blue-light mode. Pericardial biopsy can even be taken under
radiologic control alone. The open jaws of the bioptome are ad-
vanced gently until the silhouette of the pericardial sac is reached.
Then the jaws are closed and the biopsy sample is taken. Seven to
10 samples should be taken to reduce sampling error. The most
meaningful diagnostic yield from pericardial biopsies can be obtained
by multiple pericardioscopically guided tissue acquisitions.
This technique is quite demanding and can be performed in only a
limited number of experienced tertiary referral centres. Pericardio-
scopy may be considered as a diagnostic method for inspection of
the pericardium and epicardium in experienced centres. It permits
safe tissue acquisition in pericardial diseases of unknown origin.
7.3 Pericardial fluid analysis, pericardial
and epicardial biopsy
Serosanguinous or haemorrhagic fluid can be found in malignant as
well as post-pericardiotomy, rheumatologic and traumatic effusions
or can be caused by iatrogenic lesions during pericardiocentesis, but
also in idiopathic and viral forms. In cases of sepsis, TB or in HIV-
positive patients, bacterial cultures can be diagnostic. Fluid cytology
can separate malignant from non-malignant effusions, which is im-
portant for effusions in tumour patients after radiotherapy of the
mediastinum. Discriminative signatures between malignant and
autoreactive effusions are higher levels of tumour markers in neo-
plastic pericardial effusion.133,206
Cytology and assessment of bacterial cultures of the fluid, histo-
logical/immunohistological evaluation of biopsy specimens and mo-
lecular analysis (PCR for microbial agents of fluid and tissue) allow a
definite aetiological diagnosis in many cases, which permits further
treatment.133
7.4 Intrapericardial treatment
In patients with a larger effusion of unknown origin, prolonged peri-
cardial drainage may allow subsequent intrapericardial treatment.
In neoplastic pericardial effusion, most frequently due to bron-
chus carcinoma or breast cancer, intrapericardial cisplatin or thiote-
pa therapy have been proposed in combination with systemic
antineoplastic treatment, which should be tailored in collaboration
with the oncologist.204
In autoreactive and lymphocytic pericardial effusion disease-
specific intrapericardial crystalloid triamcinolone (300 mg/m2
body surface) may be considered.64 Viral pericarditis may be ex-
cluded by PCR in fluid and tissue specimens, but such investigations
are not usually performed in uncomplicated cases in clinical practice.
In cases of uraemic pericardial effusion, intrapericardial therapy
with triamcinolone may be considered, apart from intensified
haemo- or peritoneal dialysis and fluid evacuation.64,65
In rare cases of recurrent effusion, balloon pericardiotomy is an
option that allows a (transient) pericardio(-pleural-)abdominal win-
dow for drainage. This approach should be avoided in neoplastic or
purulent effusions.
7.5 Pericardial access for
electrophysiology
First reported in 1996,231pericardial access has been used for the
mapping and ablation of epicardial substrates of ventricular tachyar-
rhythmias with improved success rates and avoidance of a surgical
procedure232,233 (see supplemental Web material and Web Table 9
for complications of the procedure).
7.6 Surgery for pericardial diseases
7.6.1 Pericardial window
A pericardial window is a cardiac surgical procedure to create a
communication, or ‘window’, from the pericardial space to the
pleural cavity. The purpose of the window is to allow a pericardial
effusion (usually malignant) to drain from the space surrounding the
heart into the chest cavity in order to prevent a large pericardial ef-
fusion and cardiac tamponade.
The window is usually performed by a cardiac surgeon, but a peri-
cardial window may be created by video-assisted thoracoscopy or
balloon pericardiotomy by a percutaneous intervention. The main
indication is represented by recurrent large effusions or cardiac
tamponade when a more complex operation such pericardiectomy
is a high risk or the life expectancy of the patient is reduced (e.g.
neoplastic pericardial disease) and the intervention is palliative.
The results of a pericardial window are less definitive since the com-
munication may close and recurrent effusions, especially loculated,
are common and may require additional interventions compared
with pericardiectomy, which is a more complex but complete
operation.105
7.6.2 Pericardiectomy
In constrictive pericarditis the treatment is pericardectomy. The
decortications should remove as much of the pericardium as pos-
sible with all constricting parietal and epicardial layers,103 – 105 but
taking care of perserving the phrenic nerves bilaterally. Only by
using sternotomy can all the constricting pericardial layers be
removed. Therefore, left anterolateral thoracotomy should be
avoided since it permits only a partial resection.
It is also necessary to liberate all of the right atrium, the superior
vena cava and especially the inferior vena cava and the inferior part
of the right ventricle adjacent to the diaphragm as far as pos-
sible.103 – 105 Only when the constricting peel is adherent and
calcified is it necessary to leave behind a few islands of the pericar-
dium. To avoid bleeding, cardiopulmonary bypass should be
employed only in cases of co-existent cardiac surgical lesions, but
cardiopulmonary bypass may be needed in stand-by, in case of the
occurrence of haemorrhagic lesions during the procedure. By
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applying these principles, the controversy over the type of oper-
ation (complete or radical or only anterior pericardiectomy) is
not an issue. In recurrent constrictive pericarditis, a repeated oper-
ation has to be done as soon as possible, ideally during the first post-
operative year. Rare patients with relapsing pericarditis can also
benefit from pericardiectomy.33
8. Perspective and unmet needs
Despite a large amount of new data and the first clinical trials
that allow clinical management to be on the road to evidence-
based medicine, there are several issues that require additional
research and clarification. The main issues and unsolved questions
include
(1) Pathophysiology and risk factors for recurrent pericarditis.
What is really ‘idiopathic recurrent pericarditis’?
(2) How is it possible to prevent pericarditis beyond colchicine?
(3) Is drug tapering useful for patients with pericarditis?
(4) What is the best treatment duration for patients with pericar-
dial diseases?
(5) New and individualized therapies for refractory recurrent
pericarditis. Are they really available and useful?
(6) Is exercise restriction really needed for patients with acute and
recurrent pericarditis?
(7) Given the high risk of constrictive pericarditis in infective peri-
carditis (i.e. tuberculous and purulent) and the promising ef-
fect of intrapericardial fibrinolysis in case reports and small
trials, is intrapericardial fibrinolysis in exudative pericarditis
really safe and efficacious? And when should it be considered
in the clinical management of patients?
(8) What interventions are required to reduce the high mortality
of tuberculous pericarditis treated with antituberculosis
medication?
(9) What actually is pericarditis with myocarditis?
(10) What are the long-term outcomes of patients with myoperi-
carditis and perimyocarditis?
(11) Aetiology and pathophysiology of isolated pericardial effusion.
What is ‘idiopathic pericardial effusion’?
(12) Is diagnosis and treatment necessary for all moderate to large
pericardial effusions?
(13) What are the indications for invasive diagnostic techniques and
their diagnostic yield in clinical practice?
(14) What is the role, value and application of intrapericardial
therapies?
(15) Is pericardiectomy really useful and indicated in refractory re-
current pericarditis?
(16) What are the causes and risk factors for constrictive
pericarditis?
(17) What is the best timing for surgical therapies in pericardial
diseases?
Ongoing basic and clinical research is warranted and needed to ad-
dress all these issues and provide additional diagnostic and thera-
peutic tools for individualized management of each patient and to
improve the prognosis.
9. To do and not to do messages
from the pericardium guidelines
Management of acute and recurrent
pericarditis
Classa Levelb
Hospital admission is recommended for high-risk
patients* with acute pericarditis
I B
Colchicine use (0.5 mg twice or once daily for
patients ,70 kg or intolerant to higher doses) is
recommended as first-line therapy for acute
pericarditis as an adjunct to aspirin/NSAIDs
therapy (3 months) and is also recommended for
recurrent pericarditis (6 months)
I A
Corticosteroids are not recommended as
first-line therapy for acute pericarditis
III C
CRP should be considered to guide the
treatment duration and assess the response to
therapy
IIa C
Recommendation for management and therapy of
pericardial effusion
Pericardiocentesis or cardiac surgery is indicated for
cardiac tamponade or for symptomatic moderate
to large pericardial effusions not responsive to
medical therapy and for suspicion of unknown
bacterial or neoplastic aetiology
I C
A triage of patients with pericardial effusion is
recommended (see Figure 3)
I C
It is recommended to target the therapy of
pericardial effusion according to the aetiology
I C
Recommendation for diagnosis and therapy of constrictive
pericarditis
CT and/or CMR are indicated as second-level
imaging techniques (after echocardiography and
chest X-ray) to assess calcifications (CT),
pericardial thickness, degree and extension of
pericardial involvement
I C
Cardiac catheterization is indicated when
non-invasive diagnostic methods do not provide a
definite diagnosis of constriction
I C
The mainstay of treatment of chronic permanent
constriction is pericardiectomy
I C
Recommendation for diagnostic work-up of pericardial
diseases
In all cases of suspected pericardial disease
first diagnostic evaluation is recommended,
with auscultation, ECG, transthoracic
echocardiography, chest X-ray and routine blood
tests, including markers of inflammation (i.e. CRP
and/or ESR), WBC count with differential, renal
function, liver tests and myocardial damage
(creatine kinase, troponin)
I C
CT and/or CMR are second-level testing for
diagnostic workup in pericarditis
I C
Further testing is indicated in high-risk patients*
according to the clinical conditions
I C
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Management of tuberculous pericarditis and effusion
In patients living in endemic areas, empiric anti-TB
chemotherapy is recommended for exudative
pericardial effusion, after excluding other causes
I C
In patients living in non-endemic areas, empiric
anti-TB treatment is not recommended when
systematic investigation fails to yield a diagnosis of
tuberculous pericarditis
III C
Standard anti-TB drugs for 6 months is
recommended for the prevention of tuberculous
pericardial constriction
I C
Pericardiectomy is recommended if the patient’s
condition is not improving or is deteriorating after
4–8 weeks of antituberculosis therapy
I C
Management of neoplastic pericardial disease
Cytological analyses of pericardial fluid are
recommended for the confirmation of malignant
pericardial disease
I B
Pericardial or epicardial biopsy should be
considered for the confirmation of malignant
pericardial disease
IIa B
Tumour marker testing should be considered for
distinguishing malignant from benign effusions in
pericardial fluid
IIa B
Systemic antineoplastic treatment is
recommended in confirmed cases of neoplastic
aetiology
I B
Extended pericardial drainage is recommended in
patients with suspected or definite neoplastic
pericardial effusion in order to prevent effusion
recurrence and provide intrapericardial therapy
I B
Intrapericardial instillation of cytostatic/sclerosing
agents should be considered since it may prevent
recurrences in patients with malignant pericardial
effusion
IIa B
CMR ¼ cardiac magnetic resonance; CRP ¼ C-reactive protein; CT ¼
computed tomography; ECG ¼ electrocardiogram; ESR ¼ erythrocyte
sedimentation rate; NSAID ¼ non-steroidal anti-inflammatory drug; TB ¼
tuberculosis; WBC ¼ white blood cell.
*High risk when there is at least one risk factor among the following: high fever
(.388C), subacute course without a clear-cut acute onset, large pericardial
effusion (i.e. diastolic echo-free space .20 mm), cardiac tamponade, failure to
respond to NSAID therapy, myopericarditis, immunodepression, trauma or oral
anticoagulant therapy.
aClass of recommendation.
bLevel of evidence.
10. Web addenda
All Web figures and Web tables are available in the online
addenda at: http://www.escardio.org/Guidelines-&-Education/
Clinical-Practice-Guidelines/Pericardial-Diseases-Guidelines-on-
the-Diagnosis-and-Management-of
11. Appendix
ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano
(Chairperson) (Spain), Victor Aboyans (France), Stephan Achen-
bach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain),
Gonzalo Baro´n-Esquivias (Spain), Helmut Baumgartner (Germany),
Jeroen J. Bax (The Netherlands), He´ctor Bueno (Spain), Scipione
Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna
Fitzimons (UK), Oliver Gaemperli (Switzerland), Paulus Kirchhof
(UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti
(Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK),
Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi
(Switzerland), Adam Torbicki (Poland), Antonio Vaz Carneiro
(Portugal), Stephan Windecker (Switzerland).
ESC National Cardiac Societies actively involved in the review
process of the 2015 ESC Guidelines on the diagnosis and manage-
ment of pericardial diseases:
Albania: Albanian Society of Cardiology, Naltin Shuka;
Armenia: Armenian Cardiologists Association, Hamayak Sisakian;
Austria: Austrian Society of Cardiology, Julia Mascherbauer;
Azerbaijan: Azerbaijan Society of Cardiology, Elnur Isayev;
Belarus: Belarusian Scientific Society of Cardiologists, Vadim Shu-
mavets; Belgium: Belgian Society of Cardiology, Guy Van Camp;
Bulgaria: Bulgarian Society of Cardiology, Plamen Gatzov;
Croatia: Croatian Cardiac Society, Jadranka Separovic Hanzevacki;
Cyprus: Cyprus Society of Cardiology, Hera Heracleous Moustra;
Czech Republic: Czech Society of Cardiology, Ales Linhart;
Denmark: Danish Society of Cardiology, Jacob Eifer Møller; Egypt:
Egyptian Society of Cardiology, Mohamed Wafaie Aboleineen;
Estonia: Estonian Society of Cardiology, Pentti Po˜der; Finland:
Finnish Cardiac Society, Jukka Lehtonen; Former Yugoslav Re-
public of Macedonia: Macedonian Society of Cardiology, Slobo-
dan Antov; France: French Society of Cardiology, Thibaud Damy;
Germany: German Cardiac Society, Bernhard Schieffer; Greece:
Hellenic Cardiological Society, Kyriakos Dimitriadis; Hungary:
Hungarian Society of Cardiology, Robert Gabor Kiss; Iceland: Ice-
landic Society of Cardiology, Arnar Rafnsson; Israel: Israel Heart
Society, Michael Arad; Italy: Italian Federation of Cardiology, Salva-
tore Novo; Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirra-
khimov; Latvia: Latvian Society of Cardiology, Peteris Stradin¸sˇ;
Lithuania: Lithuanian Society of Cardiology, Ausra Kavoliuniene;
Luxembourg: Luxembourg Society of Cardiology, Andrei Co-
dreanu; Malta: Maltese Cardiac Society, Philip Dingli ; Moldova:
Moldavian Society of Cardiology, Eleonora Vataman; Morocco:
Moroccan Society of Cardiology, Mustapaha El Hattaoui; Norway:
Norwegian Society of Cardiology, Stein Olav Samstad; Poland: Pol-
ish Cardiac Society, Piotr Hoffman; Portugal: Portuguese Society
of Cardiology, Luı´s Rocha Lopes; Romania: Romanian Society of
Cardiology, Doina Ruxandra Dimulescu; Russia: Russian Society
of Cardiology, Grigory P Arutyunov; Serbia: Cardiology Society
of Serbia, Milan Pavlovic; Slovakia: Slovak Society of Cardiology,
Juraj Du´brava; Spain: Spanish Society of Cardiology, Jaume Sagrista`
Sauleda; Sweden: Swedish Society of Cardiology, Bert Andersson;
Switzerland: Swiss Society of Cardiology, Hajo Mu¨ller; The
Netherlands: Netherlands Society of Cardiology, Berto
J. Bouma; Turkey: Turkish Society of Cardiology, Adnan Abaci ;
UK: British Cardiovascular Society, Andrew Archbold; Ukraine:
Ukrainian Association of Cardiology, Elena Nesukay.
†Affiliation: Massimo Imazio, Coordinator, Cardiology Depart-
ment, Maria Vittoria Hospital and Department of Public Health and
Pediatrics, University of Torino, Torino, Italy. Email: massimo.
imazio@unito.it
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